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Molecular Characterization of Glioblastoma Cancer Stem Cells
Abstract
Malignant gliomas are locally aggressive, highly vascular tumors that have an overall survival time less
than 14 months, and current therapies provide little improvement in the disease course and outcome.
While glioblastoma multiforme (GBM) patients present uniform histological phenotypes, the molecular
determinants of the disease vary considerably between individual cases resulting in complicated
prognosis. The heterogeneity, aggressiveness and rapid tumor relapse of GBM is believed to be sustained
by cancer stem-like cell populations that are able to initiate and maintain tumors. Although CSCs
represent only a small fraction of cells within a tumor, their high tumor-initiating capacity and therapeutic
resistance is believed to drive tumorigenesis. Therefore, it is imperative to improve our molecular
understanding of the tumor initiating cells and identify pathways associated with CSCs in order to devise
innovative strategies to selectively target them. In this study, Glioma CSCs were isolated and maintained
in vitro using an adherent culture system and shown to have constitutive activation of the STAT3/NF-κB
signaling pathways and upregulation of STAT3 and NF-κB-dependent genes. Gene expression profiling
also found components of the Notch pathway as being deregulated in glioma CSC, which were sensitive
to treatment with STAT3 inhibitors. We also identified two CSC populations that produce Classical or
Mesenchymal GBM tumors but display identical histological features. Adherent CSC-derived
Mesenchymal GBM xenografts were found to exhibit high STAT3 and ANGPTL4 expression levels
compared to Classical tumors. This subpopulation of glioma CSCs formed tumors with histopathological
features of GBM and were enriched for stem cell markers, transcriptional networks and pro-angiogenic
markers characteristic of the Mesenchymal subtype. Molecular characterization of aggressive
Mesenchymal GBM xenografts identified high STAT3 and ANGPTL4 expression levels within the CD133+
CSC subpopulation, and these proteins were shown to colocalize within GBM stem cells. Elevated STAT3
and ANGPTL4 expression was found to correlate to short-term survival of human GBM patients, and a link
in expression levels was observed between the genes in individual patient samples. The deregulated
expression of these genes in glioma CSCs was sensitive to the kinase inhibitors, WP1066 and Sorafenib,
and targeted inhibition of STAT3 and ANGPTL4 was found to decrease stem cell marker expression within
tumors and lead to tumor regression. Taken together, these studies reveal that multiple CSC populations
exist within GBM that drive molecular heterogeneity and tumorigenesis. Establishing an adherent CSC
culture that maintains a Mesenchymal GBM signature provides a valuable and accurate model of the
human disease, which will give insight into the role in tumor progression of novel genes as well as their
utility as new therapeutic targets. The constitutive activation of STAT3 and NF-κB signaling pathways
found in glioma CSCs that regulates Notch signaling, as well as, the important relationship established
between STAT3 and ANGPTL4 in Mesenchymal GBM stem cells provides potential therapeutic value as
biomarkers in targeting the CSC subpopulation of GBM.
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ABSTRACT
Malignant gliomas are locally aggressive, highly vascular tumors that have an
overall survival time less than 14 months, and current therapies provide little
improvement in the disease course and outcome. While glioblastoma multiforme (GBM)
patients present uniform histological phenotypes, the molecular determinants of the
disease vary considerably between individual cases resulting in complicated prognosis.
The heterogeneity, aggressiveness and rapid tumor relapse of GBM is believed to be
sustained by cancer stem-like cell populations that are able to initiate and maintain
tumors. Although CSCs represent only a small fraction of cells within a tumor, their high
tumor-initiating capacity and therapeutic resistance is believed to drive tumorigenesis.
Therefore, it is imperative to improve our molecular understanding of the tumor initiating
cells and identify pathways associated with CSCs in order to devise innovative strategies
to selectively target them.
In this study, Glioma CSCs were isolated and maintained in vitro using an
adherent culture system and shown to have constitutive activation of the STAT3/NF-κB
signaling pathways and upregulation of STAT3 and NF-κB-dependent genes. Gene
expression profiling also found components of the Notch pathway as being deregulated in
glioma CSC, which were sensitive to treatment with STAT3 inhibitors. We also
identified two CSC populations that produce Classical or Mesenchymal GBM tumors but
display identical histological features. Adherent CSC-derived Mesenchymal GBM
xenografts were found to exhibit high STAT3 and ANGPTL4 expression levels
compared to Classical tumors. This subpopulation of glioma CSCs formed tumors with
histopathological features of GBM and were enriched for stem cell markers,
transcriptional networks and pro-angiogenic markers characteristic of the Mesenchymal
subtype. Molecular characterization of aggressive Mesenchymal GBM xenografts
identified high STAT3 and ANGPTL4 expression levels within the CD133+ CSC
subpopulation, and these proteins were shown to colocalize within GBM stem cells.
Elevated STAT3 and ANGPTL4 expression was found to correlate to short-term survival
of human GBM patients, and a link in expression levels was observed between the genes
in individual patient samples. The deregulated expression of these genes in glioma CSCs
was sensitive to the kinase inhibitors, WP1066 and Sorafenib, and targeted inhibition of
STAT3 and ANGPTL4 was found to decrease stem cell marker expression within tumors
and lead to tumor regression.
Taken together, these studies reveal that multiple CSC populations exist within
GBM that drive molecular heterogeneity and tumorigenesis. Establishing an adherent
CSC culture that maintains a Mesenchymal GBM signature provides a valuable and
accurate model of the human disease, which will give insight into the role in tumor
progression of novel genes as well as their utility as new therapeutic targets. The
constitutive activation of STAT3 and NF-κB signaling pathways found in glioma CSCs
that regulates Notch signaling, as well as, the important relationship established between
STAT3 and ANGPTL4 in Mesenchymal GBM stem cells provides potential therapeutic
value as biomarkers in targeting the CSC subpopulation of GBM.
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CHAPTER 1.

INTRODUCTION

Significance of Transcription Factors in Tumorigenesis
Transcription factors (TFs) are important cellular components that control gene
expression by gauging environmental cues to determine cell fate. Cells must recognize
and respond appropriately to various internal and external stimuli to coordinate
appropriate gene expression [1]. TFs bind to specific DNA sequences of genes and
determine whether or not the gene will be transcribed. The control region of a gene
includes specific segments of DNA called enhancers where transcription factors bind
most often in multi-protein complexes. This attracts RNA polymerase II (pol II) and
alters the chromatin structure by impacting histone proteins that package chromosomal
DNA. An environment is then created that enables pol II to initiate and elongate an RNA
transcript to regulate gene expression [2]. TFs can exercise great power since a single TF
can simultaneously affect the expression of a large cohort of downstream genes. In
maintaining expression of numerous genes, the transcriptional regulatory system plays a
central part in controlling many biological processes such as cell cycle progression,
cellular differentiation, and transformation [3-5]. It is through this same regulatory
system that numerous diseases arise due to changes in the activity and regulatory
specificity of TFs.
Deregulated expression and activation of TFs as well as mutations and
translocations play critical roles in tumorigenesis. Most oncogenic signaling pathways
converge on sets of transcription factors that ultimately control gene expression patterns
that promote tumor formation, progression and metastasis [6]. Aberrant activation of
these TFs is the result of numerous mechanisms such as changes in expression, protein
stability, protein interactions and post-translational modifications, which leads to
deregulated expression of multiple gene sets involved in cancer cell survival,
proliferation, angiogenesis and metastasis [7]. Since transcriptional regulators are
generally inactive in normal physiological conditions and their expression and activities
are tightly regulated, TFs could serve as necessary and suitable therapeutic targets in
inhibiting cancer development and progression. A limited number of transcription factors
are overactive in a large percentage of cancers; of those are the latent cytoplasmic
transcription factors STAT3, NF-κB and Notch intracellular domain (NICD) [8, 9].
STAT3 and Cancer
Signal Transducers and Activators of Transcription (STATs) are a family of latent
cytoplasmic proteins that act as signal messengers and transcription factors and
participate in normal cellular responses to cytokines and growth factors [6]. To date,
there are seven STAT family members identified: STAT1, 2, 3, 4, 5a, 5b and 6; all of
which are located in the cytoplasm in an inactive state in resting cells [10]. STAT3 was
originally identified as the transcription factor responsible for the induction of acute
phase response genes, but STAT3 is activated through tyrosine phosphorylation
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(pSTAT3) by a wide variety of factors, suggesting that it integrates diverse signals into
common transcriptional responses [11-13]. As shown in Figure 1-1, STAT3 activations
begins most commonly when JAK tyrosine kinases associate with cytokine receptors and
initiate a three-step tyrosine phosphorylation cascade:
JAK(pTyr)-receptor(pTyr)-STAT(pTyr). G-protein coupled receptors as well as growth
factor receptors can also activate STATs directly or by recruiting other non-receptor
tyrosine kinases. Following tyrosine phosphorylation, the SH2 (src homology 2) domains
of STAT3 dimerize by reciprocal phosphotyrosine interactions. STAT3 proteins then
bind to importins and translocate to the nucleus and activate gene transcription [14, 15].
STAT3 has a diverse physiological role due to the many genes it regulates, such as: genes
involved in cell cycle progression (Cyclin D1, D2, and cMyc), cell survival (Bcl-xL,
Bcl-2, and Mcl-1), invasion (MMP2 and MMP9), and angiogenesis (VEGF and HIF-1).
Due to the critical role of STAT3 in cells, it has a precise activation and deactivation
cycle. Dysregulation at any level, whether it be cytokines, growth factors, or tyrosine
kinases, can lead to increased activation and tumorigenesis [10, 16].
Constitutively active STAT3, that is tyrosine phosphorylated STAT3 (pSTAT3),
has been found in a wide variety of human cancer cell lines and primary tumors.
Normally, tyrosine phosphorylation of STAT3 protein is switched on and off in response
to signals that control cell growth and development. However, in oncogenically
transformed cells continuously activated STAT3 relays messages to the nucleus to
promote transformation and tumorigenesis [17]. Gene knockout studies have revealed the
importance of STAT3 in normal cells and development, as STAT3 null mice proved to be
embryonic lethal [18]. It has also been demonstrated that cancer cells are addicted to
STAT3 activity when compared to their normal counterpart. Several studies have
revealed that inhibition of STAT3 signaling lead to apoptosis in tumor cells, while
normal cells were able to survive at much lower levels through alternative mechanisms
[19]. Evidence suggests that STAT3 activation plays a critical role in every step of tumor
progression.
Malignant transformation of cells by various protein tyrosine kinases, oncogenes,
and viruses are all mediated through STAT3 activation. STAT3 also promotes cellular
proliferation and survival. Constitutive STAT3 signaling is associated with upregulation
of Cyclin D1 and cMyc expression, resulting in accelerated cell-cycle progression [20].
Consistent with its role in proliferation, STAT3 signaling provides survival signals and
suppresses apoptosis in cancer cells in part through the upregulation of Bcl-2, Bcl-xL,
and Mcl-1 [21]. Invasion to the extracellular matrix is another key step in tumorigenesis
that STAT3 actively participates in. Several studies reveal that overexpression of
pSTAT3 correlates with increased invasion and metastasis through the direct regulation
of matrix metalloproteinases (MMPs) [22-24]. Evidence also suggests that STAT3
activity plays a role in cellular migration under normal as well as pathological conditions.
STAT3 is crucial to wound healing and cell migration and also controls the directional
movements of cells through Rac1 and Rho GTPase regulation [25, 26]. Lastly, the
constitutive activation of STAT3 promotes angiogenesis through direct transcriptional
activation of vascular endothelial growth factor and hypoxia-inducible factor-1α [27-29].
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Figure 1-1.

The STAT signaling pathway.

STAT transcription factors are activated via a tyrosine phosphorylation cascade following
ligand binding. The activated STATs subsequently move into the nucleus where they
bind specific DNA sites as homo or heterodimers to stimulate transcription of genes.
Reprinted with permission from Darnell, J.E., Jr., Transcription factors as targets for
cancer therapy. Nat Rev Cancer, 2002. 2(10): p. 740-9.
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Due to widespread occurrence of persistent STAT3 activation in cancer and its various
roles in tumor progression, the transcriptional activator is a prime anti-cancer target.
NF-κB and Cancer
Nuclear Factor of κB (NF-κB) is a family of latent transcription factors found
inactive in the cytoplasm as homo- or heterodimers in cells. The NF-κB family includes
at least five members: NFκB1 (constitutively processed to p50), NFκB2
(stimulus-induced processing to p52), RelA (p65), RelB and cRel, with the most common
heterodimer being p50-p65 [14]. The NF-κB transcription factor was originally identified
by its role in B-cell specific gene expression and is now known to be crucial in
inflammatory and immune response to cellular injury. Further studies have shown that
diverse stimuli converge on the NF-κB family in most cell types, leading to transcription
and regulation of large genes sets involved in many biological processes [30]. Under
most circumstances, NF-κB signaling is silent and sequestered in the cytoplasm through
the binding of inhibitory proteins called IκBs. However, NF-κB is activated by diverse
signaling pathways, including extracellular factors involved in inflammatory response,
tumor necrosis factor-α (TNF-α), type I interferons, Interleukin-1 (IL-1),
lipopolysaccharides, UV radiation, viruses, and reactive oxygen species [6]. As shown in
Figure 1-2, various stimuli promote the dissociation of the cytosolic inactive NF-κB/IκB
complexes via IκB kinase (IΚΚ) activation, which results in the serine phosphorylation
and degradation of IκB. The smaller NF-κB subunit, p50, is derived by proteolytic
cleavage of a p100 translation product, which is retained in the cytoplasm. Upon release,
the p50 subunit binds p65 in the cytoplasm to form an active transcription factor. The
nuclear localization sequences that are exposed on p65 following IκB degradation allow
the heterodimer to bind importins and translocate into the nucleus and participate in
transcriptional activation [31-33].
NF-κB is involved in many biological processes by directly regulating the
expression of inflammation response genes including cytokines and chemokines, acute
phase proteins, cell adhesion proteins, immunoglobulins, viral genes as well as cell cycle
regulatory and anti-apoptotic genes [34-37]. While activation of NF-κB is found in
normal cells, it is constitutively activated in many human tumors. NF-κB binding activity
is shown to be higher in 85% of nuclear extracts from mammary tumors when compared
to normal mammary glands, and constitutive activation has been found in 83% of human
pancreatic cancer cell lines [34]. Furthermore, the inhibition of p65 in thyroid cancer cell
lines led to a decrease in cMyc expression and a reduction in cell growth. NF-κB is
believed to contribute to tumorigenesis through the regulation of genes that promote
tumor cell survival, proliferation, migration and therapeutic resistance [38-42].
A critical event in tumorigenesis is prolonged cell survival, and many studies
prove that aberrant activation of NF-κB can provide this anti-apoptotic signal. A number
of NF-κB-inducible genes that inhibit apoptosis have been identified, including Bcl-2,
TRAF1, TRAF2 and A20 [43]. NF-κB can contribute to tumorigenesis in ways other than
inhibition of apoptosis; it is shown to directly stimulate cell proliferation through
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Figure 1-2.

The NF-κB signaling pathway.

Following receptor ligation and recruitment of receptor proximal adaptor proteins,
signaling to IKK proceeds through TRAF/Rip complexes, generally in conjunction with
TAK1, leading to canonical NF-κB signaling. IKK activation results in IκB
phosphorylation and degradation. Phosphorylated NF-κB dimers bind to DNA elements
and induce transcription of target genes. Reprinted with permission from Hayden, M.S.
and S. Ghosh, Shared principles in NF-kappaB signaling. Cell, 2008. 132(3): p. 344-62.
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activation of the proto-oncogenes cMyc and Cyclin D1 [44, 45]. The migration of cancer
cells into and out of vessel walls that leads to metastasis is also attributed to constitutive
activation of NF-κB. NF-κB regulates expression of cell adhesion molecules, so its
activation leads to extravasation through increased gene expression of VCAM-1,
ICAM-1 and ELAM-1 [46-48]. The dependence of cancer cells on oxygen for survival is
also supported by NF-κB activity. The transcription factor regulates expression of
angiogenic growth factors and cytokines, such as VEGF, TNF and MCP-1, to promote
angiogenesis and tumor progression [49-51]. The constitutive NF-κB activity in many
cancer types and its multiple roles in tumor development make this transcriptional
activator an attractive target in treating cancer.
Transcription Factor Activity in Glioblastoma
Malignant gliomas are the most common type of primary brain tumor and the
most prevalent cancer of the central nervous system. While the incidence of glioma is
low compared to solid tumors in other organ systems, low survival rates make these
tumors the leading cause of cancer-related death in the young to middle-aged populations
[52]. Pathological studies indicate that gliomas arise in the cerebral hemispheres along
the cortical/subcortical interface and feature enhanced mitoses and necrosis through
histological analysis [53]. Malignant gliomas are locally aggressive, highly vascular
tumors that are very difficult to treat. The median survival for patients with glioblastoma
multiforme (GBM), the most common and aggressive subtype of glioma, has remained at
around one year for several decades [54]. Surgical resection of GBM remains the primary
treatment modality, as present adjuvant therapies provide little improvement in the
disease course and outcome. It is believed that effective treatments can be developed
once the genetic and molecular mechanisms that lead to glioma initiation and progression
are discovered.
The malignant transformation of cells can be attributed to aberrant activation of
STAT3, which leads to dysregulation of genes involved in the cell cycle and apoptosis.
High persistent activation of STAT3 is found in diverse human tumors, including gliomas
[15, 17]. Constitutively active STAT3, as assessed by tyrosine phosphorylation, is
frequently expressed in high-grade gliomas and found to correlate with tumor grade and
poor patient survival [55]. Elevated levels of pSTAT3 have been observed in GBM
tissues compared with control tissue. Studies also show that STAT3 is one of the major
regulators of mesenchymal transformation, which leads to the hallmark phenotype of
tumor aggressiveness in GBM [56]. The activation of STAT3 and JAK2 in GBM can be
attributed to the dysregulation of many proteins and pathways. The STAT3 activator,
IL-6, is highly expressed in human GBMs and corresponds to increasing tumor grade and
decreased patient survival [57]. IL-6 is also shown to act through STAT3 to regulate
VEGF expression and promote angiogenesis [58]. Persistent STAT3 signaling in GBM is
also a result of low expression levels of the protein inhibitor of activated STAT3 (PIAS3)
in glioma samples [59]. The effective inhibition of STAT3 signaling in GBM animal
models is found to decrease tumor growth and enhance apoptosis, confirming the
importance of STAT3 activation in glioma progression [60].
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The NF-κB family of transcription factors is also found to be aberrantly
upregulated in a variety of human cancers, including gliomas [61]. Studies show that
levels of NF-κB activity, as measured by serine phosphorylation, are much higher in
GBM tissue compared to normal tissue and correlate with increasing grade in
astrocytoma tumors [62, 63]. While the exact process leading to NF-κB activation in
glioma is still unclear, there are numerous proteins and pathways dysregulated in glioma
that result in constitutive NF-κB activity. TNF-α, one of the most common activators of
NF-κB, is produced in the central nervous system (CNS) by microglia, neurons,
astrocytes, and endothelial cells [64]. In GBM, TNF-α signals through TNFR1 to
promote NF-κB activation and subsequent anti-apoptotic responses [65]. Furthermore,
the levels of TNFR1 expression are elevated in GBM as compared with other low-grade
gliomas, suggesting TNF-α and TNFR1 activate NF-κB signaling and gene transcription
to promote tumor progression [66]. Numerous growth factors and signaling pathways
dysregulated in gliomas, such as EGF and PDGF, also lead to the persistent activation of
NF-κB. Through binding their respective receptors, both EGF and PDGF activate NF-κB
by a PI3K-AKT-IKK dependent mechanism to promote glioma cell survival [67, 68]. In
addition, the expression of the ubiquitin-editing protein A20, a negative regulator of
NF-κB, is diminished in GBM and is associated with the acquired resistance of cancer
cells to O6-alkylating agents like TMZ [69]. Studies reveal that inhibition of NF-κB
activity and NF-κB-regulated genes leads to a reduction in GBM growth, invasion and
angiogenesis, suggesting a strong correlation between NF-κB activation and
gliomagenesis [70].
Activity of STAT3 and NF-κB in Glioma Cancer Stem Cells
For many cancers the tumorigenic process may be initiated and sustained by a
rare, stem cell-like subpopulation, denoted cancer stem-like cells (CSCs) [71]. These
cells behave similarly to normal stem cells in that they can self-renew and generate
differentiated progeny, but they form tumors upon serial transplantation into host mice
and recapitulate the tumor phenotype [72]. The stem cell markers Nestin, Sox2 and
CD133 have been used to identify GBM CSCs [73]. A number of in vitro and in vivo
studies have demonstrated that human tumor cells with stem cell properties are required
for the growth and progression of glioma tumors. CD133 levels have even been shown to
correlate with tumor grade and be a predictive marker of GBM survival [74]. Although
CSCs represent a small population of cells within a tumor, their high tumor-initiating
capacity and therapeutic resistance drives tumorigenesis. With the discovery of CSCs,
new complexities in cancer therapy have been revealed. The ineffectiveness of current
therapies probably reflects their lack of potency on the CSC subpopulation, which
remains viable and commonly leads to tumor regeneration and metastasis [75].
Tumor-initiating cells in several solid tumor types including glioma, breast, colon,
and lung cancer have been enriched using the classical tumorsphere culture system. To
maintain cells in this culture condition, the exclusion of serum and the addition of growth
factors are always required [76]. While stem cell expansion has been successful, the
tumorsphere method has several important limitations. Sphere aggregation restricts true
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clonal analysis, spontaneous cell differentiation commonly occurs, and there is a high
percentage of apoptosis within the stem cell population. These problems limit the study
of stem cell behavior and marker analysis, so the true nature of CSCs is difficult to
determine [77]. Establishing an adherent culture system for GBM stem cells as shown in
Figure 1-3 that allows for long-term expansion of pure CSC populations would provide a
valuable and accurate model of the human disease for future studies [78, 79]. Maintaining
GBM stem cells in vitro that retain cancer-initiating properties is a critical step to
understand the biological function and nature of these cells. The characterization of GBM
stem-like cells will give insight into novel genes involved in glioma tumor progression
and lead to the discovery of new molecular markers that are predictive of metastatic
disease.
Recent studies have examined the roles of STAT3 and NF-κB in glioma CSCs.
STAT3 is constitutively activated by virtue of its tyrosine phosphorylation in GBM CSCs
and required for their proliferation and survival. Selective inhibition of STAT3 abrogates
CSC proliferation, suggesting that self-renewal for GBM stem-likes cells depends on the
presence of STAT3 [80]. Following treatment with targeted small molecule inhibitors of
STAT3 DNA binding, single glioma cells could no longer form neurospheres. This same
treatment also resulted in a loss of stem cell marker expression, suggesting STAT3 is
required for maintenance of the stem-like characteristics of these cells [81]. Targeting
STAT3 activity also sensitizes glioma CSCs to the inhibitory action of TMZ, which
strongly demonstrates the therapeutic potential of STAT3-targeted therapy in treating
GBM. The role of NF-κB signaling in glioma CSCs is not well defined. Studies reveal
that genes regulated by NF-κB are more highly expressed in U87 glioma cells that are
CD133 positive when compared to the CD133 negative population [82]. Recent findings
suggest that activation of the NF-кB pathway plays a critical role in the maintenance of
GBM stem cells. CD133 positive glioma CSCs were shown to undergo morphological
changes following IKK inhibition and gene expression analysis under the same
conditions revealed downregulation of stem cell markers while the astrocytic marker,
GFAP, was upregulated [83]. Taken together, the two pathways regulate genes important
to cell fate determination, survival, proliferation and maintenance of stem cells and
represent potential therapeutic targets in treating GBM [84].
STAT3 and NF-κB Regulation of Notch Signaling
Studies suggest a complex relationship between the STAT3 and NF-κB pathways
in glioma tumor progression [85]. Crosstalk between the two pathways has been
demonstrated at multiple levels, including activation of STAT3 by NF-κB-inducible
factors and STAT3 regulation of NF-κB processing and nuclear translocation [86]. Both
transcription factors appear to regulate the expression of numerous overlapping genes
that promote cell survival, proliferation and angiogenesis. Our studies in Chapter 2 reveal
that adherent glioma CSCs show constitutive activation of the STAT3/NF-κB signaling
pathways and upregulation of STAT3- and NF-κB-dependent genes. It was also found
that crosstalk occurs between STAT3 and NF-κB in GBM stem cells, which leads to the
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Figure 1-3.

In vitro expansion method of GBM cell lines.

Human GBM patient-derived xenografts were maintained in mice. Cell were isolated
from tissue and grown as short-term xenolines in DMEM media with fetal bovine serum
or under adherent and low-adhesion stem cell conditions in serum-free media with
additional growth factors.
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activation of NOTCH signaling. The Notch family is a highly conserved cell signaling
system expressed in most multicellular organisms. To date, four Notch genes have been
identified (NOTCH 1-4) and five ligands (Delta-1, Delta-3, Delta-4, Jagged-1 and
Jagged-2) that trigger Notch signaling.
Notch signaling is activated upon cell-cell contact as a result of interactions
between Notch receptors and their ligands. At the molecular level, triggering of Notch
receptor by ligand binding promotes two proteolytic cleavage events at the Notch
receptor. The first cleavage is catalyzed by the ADAM-family of metalloproteases,
whereas the second is mediated by g-secretase, an enzyme complex containing presenilin,
nicastrin, PEN2 and APH1. The second cleavage releases the Notch intracellular domain
(NICD), which translocates to the nucleus and activates transcription [87]. Several genes
involved in cell proliferation and apoptosis have been identified as target genes of Notch,
including the Hes family (Hairy enhancer of split family), NF-κB family (p65, p50, RelB
and cREL), Cyclin D1 and c-Myc. Multiple oncogenic pathways, such as NF-κB, Shh,
mTOR, Ras, Wnt, EGF and PDGF have been reported to crosstalk with Notch,
suggesting an important role for Notch is tumorigenesis [88].
Notch signaling plays a key role in the normal development of many tissues and
cell types through regulation of differentiation, survival and proliferation. Since
dysregulation of these biological processes results in malignant transformation, Notch
activation contributes to cancer development in various ways [89]. Aberrant activation of
Notch signaling has been reported in many tumor types, including glioblastoma. In solid
tumors, constitutive activation of the Notch pathway can occur through multiple
mechanisms, such as overexpression of ligands or loss of negative regulators. Studies
show that elevated expression of NOTCH-1 and JAGGED-1 is associated with poor
prognosis and patient survival in breast and prostate cancer [90, 91]. It is through
regulation of genes that promote survival and cell cycle progression like Bcl-xL, p21, Rb
and NF-κB that Notch activation contributes to cancer [92]. Notch signaling also plays a
major role in the maintenance and progression of tumors by promoting the
epithelial-to-mesenchymal transition and angiogenesis. Elevated Notch expression in
cancer cells is found to correlate with resistance to radiation and chemotherapeutic agents
[93]. Recently, an emerging role of Notch in cancer stem cells has been revealed in which
the Notch signaling pathway controls self-renewal and multi-potency.
Notch, STAT and NF-κB signaling pathways fulfill overlapping roles in the
regulation of proliferation, differentiation and apoptosis, but no coordinated mechanism
exists to explain their relationship [94]. Studies show that Hes binding mediates crosstalk
between Notch and STAT signaling pathways. Constitutively active Notch upregulates
the expression of Hes proteins that drive the interaction of JAK2 and STAT3, and
subsequently results in STAT3 phosphorylation and activation [95]. In gastric cancer, the
activated Notch1 receptor upregulates Twist and pSTAT3 to promote migration and
invasion of tumor cells. It has also been reported that STAT3 acts through the Notch
ligand Delta-like 1 to maintain neural precursors and potentially other stem cell
populations. Growing evidence suggests a collaboration of Notch and NF-κB signaling in
normal development and cancer. Increased Notch activation leads to induction of NF-κB
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activity, while inhibition of Notch signaling decreases NF-κB. The same effect is
observed in Notch signaling when NF-κB is activated or inhibited [96, 97]. Studies also
reveal that the p65 subunit of NF-κB acts in synergy with NICD to remove co-repressors
from the Hes-1 promoter and increase transcriptional activity [98]. Taken together, the
overactivation of Notch signaling in cells and CSCs in combination with STAT3 and
NF-κB play crucial roles in tumorigenesis and represent novel therapeutic targets in
treating glioma.
Angiogenesis and STAT3
Angiogenesis is the formation of new blood vessels from the pre-existing
vasculature. It is an essential process in reproduction, development and wound repair but
is also involved in cancer progression [99]. Tumor angiogenesis is the proliferation of a
network of blood vessels that penetrates into cancerous growths, supplying nutrients and
oxygen and removing waste products. Tumor angiogenesis actually starts with cancerous
tumor cells releasing molecules that send signals to surrounding normal host tissue. This
signaling activates certain genes in the host tissue that, in turn, make proteins to
encourage growth of new blood vessels. The complex multistage process is orchestrated
by various pro- and anti-angiogenic factors, including vascular endothelial growth factor
(VEGF), basic fibroblast growth factor (bFGF), thrombospondin, angiopoietins, and most
recently angiopoietin-like proteins (ANGPTLs) [100, 101].
Angiogenesis is also regulated by a number of signal transduction pathways.
Accumulating evidence reveals that STAT3 plays an important role in angiogenesis
through regulation of pro-angiogenic genes. STAT3 is a direct transcriptional activator of
vascular endothelial growth factor (VEGF), the most potent angiogenic molecule [102].
Studies indicate that constitutive activation of STAT3 upregulates VEGF expression and
subsequently tumor angiogenesis in melanoma and pancreatic cancer cells [27, 103].
Furthermore, inhibition of STAT3 leads to a decrease in VEGF activity and angiogenesis.
STAT3 is also involved in VEGF receptor signaling in endothelial cells, where upon its
inhibition, migration and vessel formation is blocked [104]. Another key mediator of
angiogenesis, hypoxia-inducible factor-1α (HIF-1α), is also shown to be induced by
STAT3 signaling. In low oxygen or hypoxic conditions, STAT3 and HIF-1α bind
simultaneously to the VEGF promoter, which leads to its maximum transcriptional
activation and promotion of angiogenesis [28].
STAT3 and ANGPTL4 Activity in Tumorigenesis
ANGPTL4 is an extracellular-matrix-associated glycoprotein secreted by cells
into the microenvironment. ANGPTL4 belongs to a family of 7 matricellular proteins that
are considered orphaned ligands because their cognate receptors remain unknown [105].
However, ANGPTL4 is commonly activated by both VEGF and HIF-1α. While first
identified for its involvement in lipid and glucose metabolism, a novel role for
ANGPTL4 in cancer progression has emerged [106]. Notably, expression of ANGPTL4
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has been identified in an in vivo hypoxia gene signature that predicts poor outcome in
multiple tumor types [107, 108]. Evidence suggests ANGPTL4 provides signals to
support several tumorigenic activities characteristic of the metastatic cascade, such as cell
proliferation, migration, survival, angiogenesis, epithelial-to-mesenchymal transition, and
the maintenance of stem cell niches [109].
As shown in Figure 1-4, tumor growth is promoted through a signaling pathway
that upregulates the expression of ANGPTL4 as a result of enhanced expression of
pro-inflammatory TGF-β via the SMAD pathway as well as COX-2–induced PGE2
signaling in carcinomas. ANGPTL4 subsequently activates NADPH oxidase to promote
tumor cell proliferation via the Src/ERK/STAT1 pathway [110]. As the aberrant growth
of cancer cells progresses, a mechanism to evade apoptosis via anoikis resistance ensures
the survival of the tumor cells through ANGPTL4-mediated inhibition of pro-apoptotic
Bcl-2 associated death promoter to activate BAD [111]. ANGPTL4 also triggers
angiogenesis to support tumor survival by supplying oxygen and nutrients needed for
growth. Studies of Kaposi sarcoma reveal that upon inhibition of ANGPTL4 by siRNA,
neovascularization and tumor progression were prevented [112]. ANGPTL4 is also
involved in tumor invasion and metastasis. ANGPTL4 was found to increase tumor
vascular permeability through integrin-mediated signaling and binding cadherins and
claudin-5 [110]. In addition, ANGPTL4 was shown to upregulate the expression of
VCAM-1 on endothelial cells through an unknown mechanism facilitating the attachment
of circulating metastatic cancer cells to endothelial cells, promoting their transendothelial
extravasation and metastatic tumor formation [113]. With the various roles of ANGPTL4
in tumor progression, a better understanding of the underlying cellular and molecular
mechanisms will reveal novel insights and the potential therapeutic value of ANGPTL4.
Studies have identified ANGPTL4 as being induced by constitutive activation of
STAT3 [114]. Recent findings in breast and renal cell carcinoma suggest that this
phenomenon is mediated by HIF-1 signaling. STAT3 was shown to activate HIF-1 target
genes, such as ANGPTL4, by binding to their promoters, interacting with HIF-1α and
recruiting the coactivators CREB binding protein (CBP), p300 and Pol II. Inhibition of
STAT3 significantly reduced ANGPTL4 expression and other HIF-1 target genes,
leading to decreased tumor growth. These results indicate that STAT3 and HIF-1 work
together to drive tumorigenesis, specifically through the activation of ANGPTL4 [115].
Our studies in Chapter 4 reveal aberrant activation of STAT3 and ANGPTL4 in adherent
GBM stem cells. STAT3 is bound to the ANGPTL4 promoter, and the proteins are
co-expressed in GBM stem cell populations. Both STAT3 and ANGPTL4 appear to be
important in stem cell maintenance and subsequent tumor initiation and progression.
Molecular Classification of Glioblastoma
Molecular subtypes of glioma as well as genes associated with tumor grade,
progression and patient survival have been identified by microarray expression profiling
[116-118]. While GBMs continue to be defined by histological criteria, reports indicate
that expression profiles are more accurate in predicting patient outcome [119].
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Figure 1-4.

The roles of ANGPTL4 signaling in cancer progression.

There are diverse roles of ANGPTL4 in human cancer. ANGPTL4 promotes cell
proliferation, helps cells evade apoptosis through anoikis resistance and promotes
transendothelial extravasation and metastatic tumor formation by increasing vascular
permeability. Reprinted with permission from Tan, M.J., et al., Emerging roles of
angiopoietin-like 4 in human cancer. Mol Cancer Res, 2012. 10(6): p. 677-88.
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Morphologically similar GBM tumors represent a mix of molecular subtypes, suggesting
a possibility of different clinical responses. Furthermore, there is potential that GBMs in
specific subtypes develop as a result of different causes or cells of origin [120].
Therefore, studying the behavior of the molecularly defined subclasses of GBM may
further our understanding of glioma pathology and aid in the development of more
effective therapies.
Genomic profiling has identified four subtypes of GBM based on robust gene
expression: Proneural, Neural, Classical and Mesenchymal. The Proneural subtype has
been associated with PDGFRA abnormalities, IDH1 and TP53 mutations and correlates
with younger patients. Most gliomas are classified as Proneural due to their
oligodrendrocytic signature, specifically secondary GBMs [121-123]. The gene
expression of the Neural class of glioma most closely resembles normal brain tissue.
These tumors have a strong enrichment for genes differentially expressed by neurons,
associating with neural, astrocytic and oligodendrocytic signatures. The Classical glioma
subtype has an astrocytic signature; commonly EGFR amplification is observed in this
tumor type along with low levels of CDKN2A and TP53. The neural precursor and stem
cell marker Nestin as well as NOTCH3 and Shh signaling pathways are highly associated
with the Classical subtype. Gliomas classified as Mesenchymal exhibit higher activity of
mesenchymal and astrocytic markers, which mimics cells undergoing the
epithelial-to-mesenchymal transition [124]. The subtype is characterized by the high
expression of the mesenchymal markers, MET and CHI3L1, as well as deletion of NF1
[125, 126]. Markers of proliferation and angiogenesis also distinguish the Mesenchymal
phenotype, suggesting an aggressive GBM tumor subtype with poor prognosis.
Emerging evidence suggests a role of transcriptional networks in regulating the
cellular transition into the Mesenchymal phenotype of GBM. STAT3 is believed to be an
initiator and major regulator of mesenchymal transformation through the reprogramming
of neural stem cells into an aberrant mesenchymal lineage. Constitutive STAT3
activation results in a loss of neuronal differentiation and increased expression of
mesenchymal proteins and genes, like smooth muscle alpha actin (SMA), fibronectin and
CHI3L1. Studies reveal that the inhibition of STAT3 leads to a collapse in the
Mesenchymal signature and reduces GBM aggressiveness [56]. The transition of glioma
cells to a mesenchymal state is also reported to be dependent on NF-κB signaling.
Findings indicate that TNF-α promotes mesenchymal differentiation through the
enrichment of CD44 positive stem cells in an NF-κB-dependent manner. NF-κB also
mediates mesenchymal reprogramming by inducing other transcription factors. While
NF-κB and STAT3 are both upregulated in Mesenchymal GBMs, TNF-α-induced p65
activation was found to precede STAT3 activation, suggesting that STAT3 acts
downstream of the NF-κB pathway [127]. A robust angiogenesis gene signature has been
shown to correlate with the Mesenchymal subtype of GBM as well. Gene expression
analysis revealed that Mesenchymal GBMs exhibit overexpression of the angiogenesis
markers VEGF, VEGFR1, VEGFR2 and ANGPTL4 [125].
The highly proliferative, pro-angiogenic and de-differentiated state of
Mesenchymal GBM tumors make them highly aggressive. The Mesenchymal signature
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has been found to correlate with poor radiation response and shorter survival in patients
with GBM. Therefore, a more detailed molecular understanding of this GBM subtype is
crucial to improve therapeutic design and patient outcome. In chapter 3, we describe
glioma CSCs that retain the Mesenchymal gene signature in vitro and in mouse
xenografts. This subpopulation of glioma cells forms tumors with histopathological
features of GBM and is enriched for stem cell markers, transcriptional networks and
angiogenesis markers. In establishing a culture system that represents the Mesenchymal
GBM subtype, it provides a valuable and accurate model of the human disease for future
studies. The characterization of the Mesenchymal subclass will give insight into novel
genes involved in glioma tumor progression and lead to the discovery of new therapeutic
targets in treating GBM.
Hypothesis and Specific Aims
Our hypothesis is that cancer stem-like cells are responsible for the generation,
growth and progression of glioblastoma multiforme (GBM). Additionally, several cancer
stem-like cell populations exist, and these cells have distinct molecular signatures. The
genes associated with these tumor-initiating subpopulations serve as molecular
biomarkers for disease prognosis and therapeutic targets in treating GBM progression.
Three aims were designed to investigate this hypothesis:
1. To characterize GBM cancer stem cells and investigate the role of transcription
factors in the tumor initiating subpopulation of GBM.
2. To examine the contribution of different GBM stem cell populations to the
promotion of tumor heterogeneity and define their specific molecular signatures.
3. To identify CSC molecular biomarkers that drive gliomagenesis and determine
whether targeting them has therapeutic potential in treating GBM.
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CHAPTER 2. CONSTITUTIVE ACTIVATION OF STAT3 AND NF-κB
SIGNALING IN GLIOBLASTOMA CANCER STEM CELLS REGULATES THE
NOTCH PATHWAY*
Introduction
Malignant gliomas are locally aggressive, highly vascular tumors that have a
dismal prognosis, and present therapies provide little improvement in the disease course
and outcome. Many types of malignancies, including glioblastoma, originate from a
population of cancer stem cells (CSCs) that are able to initiate and maintain tumors.
Although CSCs only represent a small fraction of cells within a tumor, their high
tumor-initiating capacity and therapeutic resistance drives tumorigenesis. Therefore, it is
imperative to identify pathways associated with CSCs in order to devise strategies to
selectively target them. In this study, we describe a novel relationship between
glioblastoma CSCs and the Notch pathway, which involves the constitutive activation of
STAT3 and NF-κB signaling. Glioma CSCs were isolated and maintained in vitro using
an adherent culture system, and the biological properties were compared to the traditional
cultures of CSCs grown as multicellular spheres under nonadherent culture conditions.
Interestingly adherent glioma CSCs show constitutive activation of the STAT3/NF-κB
signaling pathway and upregulation of STAT3- and NF-κB-dependent genes. Gene
expression profiling also identified components of the Notch pathway as being
deregulated in glioma CSCs, and the deregulated expression of these genes was sensitive
to treatment with STAT3 inhibitors. This finding is particularly important because Notch
signaling appears to play a key role in CSCs in a variety of cancers, and controls cell fate
determination, survival, proliferation and the maintenance of stem cells. The constitutive
activation of STAT3 and NF-κB signaling pathways that leads to regulation of Notch
pathway genes in glioma CSCs identifies novel therapeutic targets for the treatment of
glioma.
Methods
Cell Culture
GBM6 (provided by Dr. C. David James, Department of Neurological Surgery,
University of California, San Francisco) and MT330 (provided Dr. Christopher Duntsch,
Department of Neurosurgery, UTHSC) human glioma cell lines were grown in
____________________________
* Reprinted with permission. Garner, J.M., et al., Constitutive activation of signal
transducer and activator of transcription 3 (STAT3) and nuclear factor kappaB signaling
in glioblastoma cancer stem cells regulates the Notch pathway. J Biol Chem, 2013.
288(36): p. 26167-76.
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monolayer culture in DMEM (Cellgro, Hemdon, VA) supplemented with 10%
heat-inactivated fetal bovine serum (Hyclone Labs, Thermo Scientific, Rockford, IL),
100 units/mL penicillin and 100 μg/mL streptomycin. GBM6 cells were continuously
maintained as subcutaneous xenografts in NSG mice, and monolayer and CSC cultures
were derived from freshly harvested tumor tissue. Adherent and spheroid glioma CSCs
were maintained in NeuroBasal-A medium (Invitrogen, Carlsbad, CA) containing 2%
B27 supplement, 2 mM L-glutamine, 100 units/mL penicillin, 100 μg/mL streptomycin,
EGF (20 ng/ml), and basic FGF (40 ng/ml). For isolation of adherent CSCs, culture flasks
were coated with 100 μg/mL poly D-lysine (Sigma-Aldrich, St. Louis, MO) for 1 hr
followed by coating with 10 μg/mL laminin (Gibco, Life Technologies Inc., Grand Island
NY) for 2 hr prior to use. Adherent CSCs were plated at 1 X 105 cells per 75 cm2 flask,
grown to confluence, dissociated with HyQTase (Thermo Scientific, Scientific, Rockford,
IL), and split 1:3. For isolation of spheroid CSCs, glioma cells were dissociated with
HyQtase and plated at ~ 1 x 105 cells/mL in ultra-low adhesion flasks.
Quantitative RT-PCR
Total RNA was extracted using the QIAshredder and RNeasy mini kits (Qiagen
Inc., Valencia, CA) according to manufacturer’s protocol. RT-PCR was performed on an
iCyclerIQ (Bio-Rad, Richmond, CA) using an iScript One-Step RT-PCR kit with SYBR
Green (Bio-Rad, Richmond, CA). Reaction parameters were as follows: cDNA synthesis
at 50 °C for 20 min, transcriptase inactivation at 95°C for 5 min, PCR cycling at 95°C for
10 sec, and 60°C for 30 sec for 40 cycles. The following primers were used for RT-PCR:
β-actin, 5′-AGAAGGAGATCACTGCCCTG-3′ (forward),
5′-CACATCTGCTGGAAGGTGGA-3′ (reverse); CD133
5’-CATCCACAGATGCTCCTAAGG-3’ (forward),
5’-AAGAGAATGCCAATGGGTCCA-3’ (reverse); SOX2
5′-GCCGAGTGGAAACTTTTGTCG-3′ (forward),
5′-GCAGCGTGTACTTATCCTTCTT-3′ (reverse); IL8
5’-TAGCAAAATTGAGGCCAAGG-3’ (forward),
5’-AGCAGACTAGGGTTGCCAGA-3’ (reverse); Trail
5’-GAGCTGAAGCAGATGCAGGAC-3’ (forward),
5’-TGACGGAGTTGCCACTTGACT-3’ (reverse); CXCL11
5’-ATGAGTGTGAAGGGCATGGGC-3’ (forward),
5’-TCACTGCTTTTACCCCAGGG-3’ (reverse); Bcl-2
5’-CCGGAGGCGCTTTACTACC-3” (forward),
5’-TAGGGGTGTAGGCAGGTTCAC-3’ (reverse); Bcl-X
5’-GGTCGCATTGTGGCCTTTTTC-3’ (forward),
5’-AGGGGCTTGGTTCTTACCCA-3’ (reverse); Caspase-3
5’-CATGGAAGCGAATCAATGGACT-3’ (forward),
5’-CTGTACCAGACCGAGATGTCA-3’ (reverse); NOTCH1
5′-GAGGCGTGGCAGACTATGC-3′ (forward), 5′- CTTGTACTCCGTCAGCGTGA-3′
(reverse); HES5 5′-AGTCCCAAGGAGAAAAACCGA-3′ (forward),
5′-GCTGTGTTTCAGGTAGCTGAC-3′ (reverse); JAG1
5’-GTCCATGCAGAACGTGAACG-3’ (forward);
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5’-GCGGGACTGATACTCCTTGA-3’ (reverse), NUMBL
5’-TGGTGGACGACAAAACCAAGG-3’ (forward),
5’-ACGACAGATATAGGAAGCCT-3’ (reverse); DTX3
5’-TCGTTCGTCCTGTCCAGAATG-3’ (forward),
5’-AAGTCTCGCCATCTATGAGGAT-3’ (reverse); DVL3
5’-GACGCCGTACCTTGTGAAG-3’ (forward); 5’-CGCTGCAAAACGCCCTTAAA-3’
(reverse); RBPJ 5’-CGGCCTCCACCTAAACGAC-3’ (forward),
5’-TCCATCCACTGCCCATAAGAT-3’ (reverse).
Immunoblot Analysis
For preparation of whole cell extracts, cells were lysed in RIPA buffer (Thermo
Scientific, Rockford, IL), containing 1 mM NaF, 1 mM Na3VO4, 1 mM PMSF and
protease inhibitor cocktail (Sigma-Aldrich, St. Louis, MO) at 4°C for 30 minutes, and
pre-cleared by centrifugation (12,000×g, 15 minutes). Nuclear extracts were prepared
using a nuclear extract kit (Active Motif, Carlsbad, CA) as previously described [31]. The
amount of protein was determined using a BCA protein assay kit (Thermo Scientific,
Pierce, Rockford, IL). Extracts (25 μg) were separated by SDS-PAGE, transferred to
polyvinylidenedifluoride membranes (Millipore Co., Bedford, MA) and immunoblotted
with antibodies against the following proteins: β-Tubulin III and GFAP (Sigma-Aldrich,
St. Louis, MO); Nestin (Abcam, Cambridge, MA); STAT3 and phospho-STAT3 (Cell
Signaling Technology, Beverly, MA); p65 and lamin (Santa Cruz Biotechnology Inc.,
Santa Cruz, CA). Followed by addition of IRDye800CW goat anti-mouse IgG or
IRDye680 goat anti-rabbit IgG antibodies(LI-COR Biosciences, Lincoln, NE). Blots were
visualized on an Odyssey Infrared Imaging System (LI-COR Biosciences, Lincoln, NE).
Immunofluorescence and Confocal Microscopy
Cells grown in 8-well chamber slides (Millipore Co., Bedford, MA) to ~50%
confluence were washed with PBS, fixed with 4% paraformaldehyde and methanol, and
permeabilized with 1% Triton X100. After blocking with 5% goat serum, cells were
incubated with nestin, STAT3, pSTAT3, and p65 antibodies, and subsequently stained
with goat anti-mouse Alexa Fluor 488 and goat anti-rabbit Alexa Fluor 555 (Invitrogen,
Carlsbad, CA). Cell were counterstained with Vectashield mounting media with DAPI
(Vector Laboratories, Burlingame, CA). Images were captured on a Zeiss LSM700 laser
scanning confocal microscope (Zeiss, New York, NY).
Tumor Xenografts in Mice
All animal experiments were performed in accordance with a protocol approved
by the Institutional Animal Care and Use Committee of the University of Tennessee
Health Science Center. Cells were dissociated with HyQTase, resuspended in PBS,
enumerated in a Coulter Counter Analyzer, and resuspended in 100 μl of PBS at the
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desired cell number for subcutaneous injections. Tumor xenografts were established in
five-week-old male NOD.CgPrkdcscid Il2rgtm1Wjl/SzJ (NSG) mice (Jackson
Laboratory, Bar Harbor, ME) by direct injection of glioma cells into the flanks. Tumors
were measured bi-weekly until reaching a volume of ~400 mm3; mice were then
sacrificed and tumors harvested.
Colony Formation Assay
Single cell suspensions of 5,000 cells in 1 ml of 0.4% agarose in tissue culture
medium were added to triplicate wells of ultralow adhesion 6-well plates. Cells were fed
twice a week with an additional 0.5 ml media. At day 14, plates were stained with MTT
(10 μg/ml) for 3 hours and colonies were counted on a light microscope.
MTT Cell Viability Assay
Glioma monolayer cells or adherent CSCs in 96-well plates were treated with
varying concentrations of WP1066 or S3I-201 (Selleckchem, Houston, TX). After 72 hr,
10 μl of MTT stock solution (10 mg/ml) was added to each well and incubated at 37°C
for 2-4 hr. MTT was solubilized by adding 100 μl of 10% SDS in 0.01N HCL and plates
incubated at 37oC for 4 hr in a humidified chamber. Plates were read at 570 nm on a
Bio-Rad plate reader.
Apoptosis Assay
The induction of apoptosis was monitored by flow cytometry on an Accuri C6
(BD Bioscience, San Jose, CA) using the Annexin V-FITC apoptosis detection kit (BD
Pharmingen, San Diego, CA), according to the manufacturer's instructions.
p65-GST Pulldown Assay
The p65 cDNA was cloned into pGEX-KG expressed in E.coli strain BL21 and
affinity-purified in glutathione-sepharose beads as previously described [128]. For
pulldown assays, nuclear extracts from glioma monolayer cells or adherent CSCs were
incubated with the p65-GST fusion protein bound to glutathione-agarose beads at 4oC
overnight. The bound proteins were washed extensively and eluted with Laemmli buffers,
resolved by SDS-PAGE (10%), blotted on PVDF membranes, and probed with
anti-STAT3.
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Microarray Analysis
Total cellular RNA was extracted from cells with TRIzol reagent (Invitrogen,
Carlsbad, CA) and submitted to the UTHSC Center of Genomics and Bioinformatics
(Memphis, TN) for labeling and hybridization to Human-HT12 BeadChips (Illumina,
Inc., San Diego, CA). Microarray data analysis was then carried out using GenomeStudio
3.4.0 (Illumina Inc., San Diego, CA) and GeneSpring software 7.0 (Silicon Genetics,
Inc., RedWood City, CA), and expression values for each gene were normalized as
described previously [129]. The average fold-change in gene expression from three
independent sets of GeneChip data for glioma monolayers and adherent CSCs was
subjected to non-parametric t testing. The microarray data were subjected to Gene
Ontology modular enrichment analysis using the Database for Annotation, Visualization
and Integrated Discovery (DAVID) [130] and the protein-protein interaction network of
the Notch pathway was determined by STRING (Search Tool for the Retrieval on
Interacting Genes/Proteins) analysis [131].
Chromatin Immunoprecipitation
Chromatin Immunoprecipitation (ChIP) was carried out using the ChIP-ITTM
Express Enzymatic kit (ActiveMotif, Carlsbad, CA) according to the manufacturer's
instructions. In brief, chromatin from cells was cross-linked with 1% formaldehyde (10
min at 22oC), sheared to an average size of 200 bp, and then immunoprecipitated with
anti-p65 or STAT3 (Santa Cruz Biotechnology Inc., Santa Cruz, CA). ChIP-PCR primers
were designed to amplify a proximal promoter region containing putative STAT3 (-1940
to -1919) and NF-κB (-2145 to -2135) binding sites in the Notch1 promoter. The primers
used were: for STAT3 site, 5’-CACTGGCTGTTTCCAGAGTG-3’ (forward),
5’-GGGAGGGACCTAGGACTGTG-3’ (reverse); for NF-κB site,
5’CTACTTGCCAGGGGCCTAC-3’ (forward), 5’-GCTCATAAGCCCGCGTTAC-3’
(reverse).
Statistical Analysis
At least three independent experiments were performed in duplicate, and data are
presented as means ± sd. ANOVA and post-hoc least significant difference analysis or
Student t tests were performed.p values < 0.05 (*) were considered statistically
significant.
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Results
Expression of CSC Markers and Tumorigenicity of Adherent CSCs
CSCs are often generated based on their ability to grow as multicellular,
nonadherent spheres in low adhesion flasks, which we denote spheroid CSCs [132, 133].
Alternatively, CSCs can also be grown in laminin-coated flasks, which we denote as
adherent CSCs [77]. To define the biological properties of adherent and spheroid CSCs
derived from glioma lines, we examined the expression of two classical stem cell markers
CD133 and Sox2. In brief, total RNA was prepared from GBM6 and MT330 gliomas,
which were grown in monolayer or under the two different CSC conditions, and the
expression of CD133 and Sox2 was determined by qPCR. As shown in Figure 2-1A,
CD133 and Sox2 gene expression was greater in both adherent and spheroid glioma
CSCs when compared to glioma cells grown in monolayer. Furthermore, as determined
by immunostaining, nestin (neural stem cell marker) was highly expressed in adherent
and spheroid glioma CSCs when compared to glioma monolayers, while βIII-tubulin
(neural differentiation marker) and glial fibrillary acid protein (astrocyte differentiation
marker) were more highly expressed in glioma monolayers (Figure 2-1B).
Since CSCs are believed to have enhanced tumorigenicity, we next compared the
tumor initiating capacity of GBM6 glioma cells grown in monolayer or as adherent
CSCs. In brief, initially 1 x 106 cells were injected subcutaneously in the flanks of NSG
mice and tumor engraftment determined by caliper measurement. As shown in Figure
2-1C, adherent glioma CSCs formed tumors rapidly and grew to ~400 mm3, while only
small tumors developed in mice injected with monolayer cultures at 40 days. The
tumorigenic potential of adherent glioma CSCs was further characterized by performing a
limiting dilution analysis. We found that as few as 10,000 glioma CSCs were capable of
consistently forming tumors, and most interestingly that the adherent CSCs were nearly
100-times more potent in inducing tumors than the glioma monolayer cultures. Soft-agar
assays for anchorage independent growth, which is used as an in vitro correlate for
tumorigenic potential, show that adherent CSCs have a 68-fold greater colony formation
potential than glioma monolayer cells, 6.8% versus 0.1%, respectively. (Figure 2-1D).
Thus, the adherent glioma cells grown in laminin-coated plates exhibit characteristics
previously ascribed to cancer stem cells, i.e. they self-renew, display neural stem cell
markers, form tumors upon serial transplantation that recapitulate the tumor phenotype,
and exhibit enhanced tumorigenicity.
Constitutive Activation of the STAT3 and NF-κB Signaling Pathways in Glioma
CSCs
The STAT3 and NF-κB signaling pathways have been found to be constitutively
active in various human cancers including glioma, and their activation is believed to play
a critical role in the stem cell phenotype. To characterize the NF-κB and STAT3
signaling pathways in glioma CSCs, we examined the intracellular localization of STAT3
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Figure 2-1.

Expression of CSC markers and tumorigenicity of adherent CSCs.

A. RNA was prepared from monolayer, and adherent and spheroid CSC cultures of
GBM6 and MT330 gliomas, and CD133 and SOX2 expression quantified by qPCR and
normalized to actin expression (n=3). Error bars, S.D. ** p < 0.01; *** p < 0.001. B.
GBM6 monolayer cells and adherent CSCs were fixed and immunostained for Nestin,
tubulin, or GFAP (green) and counterstained with DAPI (blue), and analyzed by confocal
microscopy. C. Mice were subcutaneously injected with varying concentrations of GBM6
cells grown in monolayer (GBM6-M) or adherent CSCs in laminin-coated plates (GBM6
Ad-C), and tumor volume was determined by caliper measurement three times per week
(n=10 per group). D. GBM6 monolayer and adherent CSC cultures were plated in softagar (10,000 cells per well of 6-well plates) and the colony formation potential was
assessed.
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and the p65 subunit of NF-κB by confocal microscopy. GBM6 glioma cells were grown
as monolayers or adherent glioma CSCs on glass slides and immunostained with
antibodies specific for STAT3, pSTAT3 (as a measure of transcriptionally active
STAT3), and p65. Cells were counterstained with DAPI to define nuclear localization of
proteins. As shown in Figure 2-2A, although STAT3 and p65 are present in the
cytoplasm and nucleus of both GBM6 glioma monolayers and adherent CSCs, their
colocalization is only evident in the nucleus of adherent CSCs. Moreover as shown in
Figure 2-2B, while tyrosine phosphorylated STAT3 is undetectable in glioma monolayer
cultures, pSTAT3 is clearly present in glioma CSCs and is selectively colocalized in the
nucleus with p65.
To further characterize the activation of the STAT3 signaling pathway in gliomas,
nuclear extracts were prepared from GBM6 cells grown under the different culture
conditions and analyzed by immunoblotting for phopho-STAT3 and STAT3. As shown
in Figure 2-2C and consistent with immunostaining results, both STAT3 and pSTAT3
were clearly detectable in nuclear extracts of glioma cells irrespective of whether they
were grown as monolayers or CSCs. However, basal activation of STAT3, as determined
by the nuclear levels of tyrosine-phosphorylated STAT3, was markedly greater in CSCs.
This finding is in contrast to normal (untransformed) cells such as fibroblasts, where
basal activation of STAT3 is undetectable. Moreover, nuclear expression of p65 is higher
in both adherent and spheroid CSCs. Thus, we provide strong evidence that the STAT3
(as measured by nuclear STAT3 and phospho-STAT3 levels) and NF-κB (as measured by
nuclear p65 levels) signaling pathways are constitutively activated in glioma cells, and
activation is markedly greater in glioma CSCs. In addition, as shown in Figure 2-2D, the
interaction between STAT3 and p65 in the nucleus is further borne out by pulldown
assays with p65-GST, which show a greater interaction of STAT3 with p65 in nuclear
extracts from adherent and spheroid CSCs.
To characterize the functional significance of constitutive activation of these
signaling pathways, we examined the expression of several STAT3 and NF-κB regulated
genes in glioma monolayer and CSCs. As shown in Figure 2-2E, the expression of
several NF-κB regulated genes (IL8, CXCL11and Trail) was significantly higher in both
adherent and spheroid glioma CSCs when compared to monolayer cultures. Most
notably, IL8 gene expression was 6-8 fold-higher in CSCs. In addition, the expression of
known STAT3-regulated genes (Bcl-2, Bcl-X and Caspase 3) was also markedly elevated
in both adherent and spheroid CSCs (Figure 2-2F). These results suggest that, since the
transcriptionally-active forms of p65 and STAT3 are colocalized in the nucleus of glioma
CSCs, the constitutively activated forms of these important transcription factors may
interact and drive the expression of critical STAT3 and NF-κB regulated genes.
The Effects of Specific STAT3 Inhibitors on Glioma Monolayers and Glioma CSCs
We next sought to determine the efficacy of STAT3 inhibitors on the
constitutively activated STAT3 pathway in CSCs. Adherent GBM6 CSCs were plated
and treated with a pharmacological inhibitor of STAT3 (WP1066 or S3I-201) for 2 hrs at

24

Figure 2-2. Constitutive activation of STAT3 and NF-κB signaling pathways in
glioma adherent CSCs.
GBM6 monolayer, and adherent CSC cultures or cultures were fixed and immunostained
with antibodies as indicated and analyzed by confocal microscopy. A. STAT3 and B.
phospho-STAT3 staining is represented in green, p65 in represented in red, and nuclear
DAPI staining in blue. White pixels represent the colocalization of STAT3 or
phospho-STAT3 and p65 proteins within the cells. C. The expression of STAT3,
pSTAT3, and p65 in nuclear extracts prepared glioma cells was determined by
immunoblotting. D. GST-p65 pulldown assays were performed to assess the interaction
of STAT3 and p65 in glioma CSCs. E. RNA was prepared from GBM6 monolayer and
adherent CSC cultures, and the expression of IL8, Trail, CXCL11, Bcl-2, Bcl-X and
Caspase-3 was quantified by qPCR and normalized to actin expression (n=3). Error bars,
S.D. * p < 0.05; ** p < 0.01.
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varying concentrations. Nuclear extracts were prepared and STAT3 and pSTAT3
expression was determined by immunoblotting. As shown in Figure 2-3A, both WP1066
and S3I-201 were extremely effective in inhibiting STAT3 tyrosine phosphorylation in
CSCs, with nearly complete inhibition of pSTAT3 at 50 μM WP1066 and 300 μM
S3I-201. However, both inhibitors had little or no effect on nuclear STAT3 levels. We
then examined the effects of WP1066 (50 μM for 2 hr) on intracellular localization of
STAT3 and the p65 subunit of NF-κB in glioma CSCs by confocal microscopy. As
shown in the upper panel of Figure 2-3B and previously in Figure 2-2A, STAT3 and p65
are colocalized in the nucleus of adherent CSCs. In contrast, treatment with WP1066
markedly inhibited the nuclear colocalization of STAT3 with p65 in GBM6 glioma CSCs
(lower panel of Figure 2-3B). Similar results were obtained when cells were
immunostained for pSTAT3 and p65, i.e. the STAT3 inhibitor ablated the nuclear
colocalization of pSTAT3 with p65.
We then examined the effects of WP1066 or S3I-201 on the cell viability or
proliferation of glioma monolayers and adherent CSCs. In brief, cells in 96-well plates
were treated with varying concentrations of the pharmacological STAT3 inhibitors for 72
hr, and cell proliferation was determined by MTT assays. As shown in Figure 2-3C,
although both inhibitors induced a dose-dependent reduction in cell number in both
glioma monolayers and adherent CSCs, there was a markedly enhanced effect of both
inhibitors on adherent CSCs. Moreover, flow cytometric analysis of Annexin V stained
cells demonstrated that treatment with the STAT3 inhibitor WP1066 had a greater effect
on the induction of apoptosis in adherent CSCs than in glioma monolayers (Figure
2-3D). Taken together these results show that STAT3 activation is greater in adherent
CSCs.
Microarray Analysis Identifies Upregulation of the Notch Pathway in Glioma CSCs
To identify genes differentially expressed in glioma CSCs, we performed a
preliminary microarray analysis. In brief, whole genome expression profiling was
performed on RNA prepared from three independent biological replicates of MT330 and
GBM6 grown as monolayers and spheroid glioma CSCs. The samples were submitted to
the UTHSC Center of Genomics and Bioinformatics (Memphis, TN) for labeling and
hybridization to HT-12 expression BeadChips (Illumina Inc., San Diego, CA). RNA
integrity was validated on an Agilent bioanalyzer, and all samples showed distinct peaks
corresponding to intact 28S and 18S ribosomal RNA. Hybridization signals were
processed using Illumina GenomeStudio software (annotation, background subtraction,
Quantile normalization and presence call filtering). GeneSpring GX software (Agilent
Technologies, Palo Alto, CA) was used for statistical computing. Functional annotation
of the genes differentially expressed in glioma CSCs revealed that genes in the Notch
signaling pathway were significantly enriched (P<0.05, DAVID Bioinformatics
Resources 6.7). The expression of these Notch pathway genes is shown in Figure 2-4A,
and their interaction with the STAT3 and NF-κB signaling pathways shown
schematically in Figure 2-4B. Most notably while Notch1, Notch3, Notch4, Hes5, Hey1
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Figure 2-3.

Effects of selective STAT3 inhibitors on adherent glioma CSCs.

A. GBM6 cells were treated with WP1066 and S3I-201 at the indicated concentrations
and the expression of STAT3, pSTAT3, and p65 proteins was determined by
immunoblotting. B. Cells were treated with WP1066 (50 μM for 2 hrs) or vehicle, and
colocalization of STAT3 and p65 was determined by immunostaining. C. Proliferation of
GBM6 monolayer and adherent CSC cultures was measured by MTT assay after
treatment (72 hr) with WP1066 or S3I-201 at the indicated concentrations. D. At 48 hrs
after treatment with 50 μM WP1066, apoptosis was determined by Annexin V staining
and quantified by flow cytometry.
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Figure 2-4.

Enrichment of the Notch signaling pathway in glioma CSCs.

A. RNA from MT330 and GBM6 monolayer and spheroid CSC cultures was prepared
and microarray analysis performed. B. Schematic representation of the interaction of the
Notch pathway with STAT3 and NF-κB signaling pathways using STRING analysis.
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and Jag1, known positive regulators of this pathway, were upregulated in glioma CSCs,
negative regulators of this pathway, CTBP1 and RBPJ, were downregulated.
The Roles of STAT3 and p65 in the Upregulation of the Notch Pathway in Glioma
CSCs
To confirm that these genes were indeed differentially regulated in CSCs, qPCR
was performed on RNA extracted from GBM6 monolayers and adherent glioma CSCs.
As shown in Figure 2-5, expression of Notch1, Hes5, Jag1, Numbl, Dtx3 and Dvl3 was
upregulated in adherent glioma CSCs, while RBPJ was downregulated. Most
interestingly, pretreatment with either STAT3 inhibitor or the NF-κB inhibitor Velcade
reduced the expression level of the genes upregulated in the CSCs to levels observed in
monolayer cultures, while these inhibitors increased the level of RBPJ expression in
glioma CSCs. Thus, these genes in the Notch pathway are regulated both by STAT3 and
NF-κB.
In addition, treatment with DAPT (γ-secretase inhibitor), which blocks Notch
activation, also reduced the expression level of the genes upregulated in CSCs, while it
increased the level of expression of RBPJ in glioma CSCs. These results are consistent
with the critical role that Notch receptor plays in the regulating multiple genes in both
normal neural stem cells and glioma CSCs [134, 135]. Since p65 and STAT3 appear to
be involved in Notch1 expression, we next examined whether they directly bind to the
Notch1 promoter. Examination of putative transcription binding sites revealed a STAT3
and a NF-κB binding site proximal to the Notch1 promoter. Specific primers were
designed and synthesized for each of these potential binding sites in the Notch1 promoter
and the binding of STAT3 and p65 was demonstrated by ChIP analysis. In brief,
protein-DNA complexes were crosslinked with formaldehyde, chromatin was sheared to
average of 200 bp and immunoprecipitated with anti-STAT3 or -p65, crosslinking
reversed and the resulting DNA sequences detected by PCR and qPCR. As shown in
Figure 2-6A, significantly increased binding of STAT3 to the Notch1 promoter was
observed in adherent CSCs as compared to glioma monolayer cultures. We then
examined whether p65 bound to the NF-κB binding site that was nearby the STAT3 site
in the Notch1 promoter. As shown in Figure 2-6B, significantly increased binding of p65
to the Notch1 promoter was also observed in adherent CSCs. Taken together these results
show that STAT3 and p65 regulate Notch1 expression in adherent CSCs by directly
binding to the Notch1 promoter.
Discussion
Numerous studies support the concept that many types of malignancies, including
glioblastoma, originate from a CSC population that is able to initiate and maintain tumors
[8, 136]. Although CSCs only represent a small fraction of cells within a tumor, their
high tumor-initiating capacity and therapeutic resistance drives tumorigenesis. Therefore,
it is imperative to identify pathways associated with CSCs in order to devise strategies to
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Figure 2-5. Effects of STAT3 and NF-κB inhibitors on the expression of
components in the Notch signaling cascade in vitro.
GBM6 cells were treated with STAT3 (50 μM WP1066 and 300 μM S3I-201), NF-κB
(10 nM Velcade) or γ-secretase (10 μM DAPT) inhibitors. RNA was prepared and the
gene expression of Notch1, Hes5, JAG1, NUMBL, DTX3, DVL3 and RBPJ quantified
by qPCR and normalized to actin expression (n=3). Error bars, S.D. * p < 0.05; **, p <
0.01; *** p < 0.001.
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Figure 2-6.
promoter.

The binding of STAT3 and the p65 subunit of NF-κB to the Notch1

ChIP analyses of A. STAT3 and B. p65 binding to Notch1 promoter. The ChIP-enriched
DNA levels analyzed by qPCR were normalized to input DNA, followed by subtraction
of non-specific binding determined by control IgG. C. The location of STAT3 and NFκB binding sites on the Notch promoter; STAT3-II and NF-κB-III were used for this
study.
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selectively target them. In this study, we describe a novel relationship between
glioblastoma CSCs and the Notch pathway, which involves the constitutive activation of
STAT3 and NF-κB signaling. Glioma CSCs were isolated and maintained in vitro using
the previously described adherent culture system [77], and the biological properties were
compared to the traditional cultures of CSCs grown as multicellular spheres under
nonadherent culture conditions [132, 133]. Under the different CSC growth conditions,
the expression of CD133, Sox2 and Nestin, which are markers of neural and brain cancer
stem cells [137], were similar but increased when compared to glioma cells grown in
monolayer. Examination of the tumorigenicity of the adherent glioma CSCs in vivo by
limiting dilution analysis showed that these cells were ~100 times more tumorigenic than
monolayer cultured glioma cells. These findings are consistent with previous studies,
which showed that CD133 expression correlated with chemoresistance of short-term
cultures of glioma cells isolated from patients with primary or recurrent tumors, and the
percentage of tumor cells expressing CD133 increased in all recurrent patient tumors
compared to the primary tumor [138]. Furthermore, 100-fold fewer CD133 positive cells
of the murine GL261 glioma line were sufficient to initiate tumors in the brain of mice
when compared to CD133-negative cells [139]. Taken together, these findings
demonstrate that adherent glioma CSCs exhibit characteristics previously described for
CSCs grown in suspension culture and thus provide a valuable model for studying glioma
CSC behavior.
The STAT3 and NF-κB pathways have been linked to cancer, and they trigger
critical target genes regulating cell proliferation and survival. Both pathways have been
found to be constitutively active in a number of human cancers including glioma, but
their role in the glioma CSC subpopulation is not well understood [140]. For example,
aberrant nuclear expression of NF-κB was found in a panel of GBM cell lines, while
untransformed glial cells did not display NF-κB activity [141]. In addition, constitutively
high STAT3 activity has been observed in a number of glioma cell lines and correlated
with poor prognosis [142]. In this study, although the STAT3 and NF-κB signaling
pathways are constitutively activated in glioma lines, we found that these pathways are
dramatically activated in glioma CSCs. For example, nuclear STAT3 and phosph-STAT3
levels found in glioma CSCs were similar to the high cytokine-induced levels found in
glioma monolayers, which at baseline were low but detectable. Moreover, NF-κB
activation in glioma CSCs was demonstrated by high levels of the p65 subunit of NF-κB
present in nuclear extracts. Furthermore constitutive activation of the STAT3 and NF-κB
pathways and their direct interaction in glioma CSCs was evidenced by confocal
microscopy of glioma CSCs stained for STAT3, pSTAT3, and p65. These STAT3 and
NF-κB proteins were colocalized in the nuclei of glioma CSCs, with the transcriptionally
active form of STAT3 (i.e pSTAT3) and p65 exclusively found in the nucleus. Evidence
of the functional significance of STAT3 and NF-κB activation in glioma CSCs was
provided by the finding that some of their known target genes (Bcl-2, Bcl-X, IL8,
CXCL11, Trail and Caspase3) were overexpressed in adherent and spheroid glioma CSCs
relative to glioma monolayers. Since targeting these signaling pathways in glioma CSCs
would be a novel approach in glioma treatment, we examined the effects of two STAT3
inhibitors, WP1066 and S3I-203, in glioma CSCs. The inhibitors blocked STAT3
tyrosine phosphorylation, thereby preventing its nuclear translocation [143]. This was
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confirmed by its ability to reduce the high basal nuclear levels of pSTAT3 in glioma
CSCs. Treatment with the STAT3 inhibitor led to loss of nuclear colocalization of these
proteins as well as their interaction. In addition, treatment with either STAT3 inhibitor
resulted in growth suppressive effect on monolayer and adherent CSC cultures, but there
was a markedly greater growth suppressive effect on glioma CSCs, suggesting that
targeted therapy of these key pathways in glioma CSCs may be possible.
To further investigate potential biomarkers in glioma CSCs, microarray analysis
was performed and revealed deregulation of the Notch signaling pathway. Notch is
involved in cell fate decisions throughout normal brain development and in stem cell
proliferation and maintenance, and its role in glioma is firmly established [84]. While the
expression of Notch1, Hes5, Jag1, Numbl, Dtx3 and Dvl3 was upregulated in glioma
CSCs, the expression of CTBP1 and RBPJ, negative regulators of Notch signaling, was
downregulated in glioma CSCs. The differential expression of these genes was validated
by qPCR. The identification of Hes5 as a potential glioma CSC biomarker is of great
interest because Hes5 appears to play an important role in neural development [144].
In addition, we defined molecular crosstalk between the STAT3, NF-κB and
Notch signaling pathways in glioma CSCs. While STAT3 inhibitors reduced expression
of Notch-related genes in glioma CSCs, they increased expression of the negative
regulator of Notch, RBPJ. It has been previously reported that in the developing central
nervous system there is crosstalk between Notch and STAT3 pathways. For example, the
activation and phosphorylation of STAT3 is mediated by the direct binding of several
Hes family members (Notch effectors) to STAT3 [95]. Interestingly, activation of the
Notch pathway leads to serine phosphorylation (Ser-727) but not tyrosine
phosphorylation (Tyr-705) of STAT3, suggesting that the constitutive activation of
STAT3 in glioma CSCs as determined by its tyrosine phosphorylation lies upstream of
Notch pathway activation [135]. These results on STAT3 activation are consistent with
previous studies on the Notch pathway in neural stem cells [134]. In addition, Notch and
NF-κB signaling pathways apparently collaborate throughout normal brain development
and function, and may regulate stem cell renewal and differentiation [94]. We
hypothesize that the interactions of STAT3, NF-κB, and Notch signaling pathways that
occur during normal brain development are deregulated in glioma CSCs. As shown in
this study, there is crosstalk between these signaling pathways in the glioma CSC
subpopulation that drives gliomagenesis. The constitutive activation of STAT3 and NFκB signaling pathways, and the upregulation of the Notch pathway in glioma CSCs
identifies novel therapeutic targets for the treatment of glioma. Future studies will be
required to validate these findings in vivo and decipher the underlying molecular
mechanisms.
Summary
In conclusion, we characterized the properties of glioblastoma cancer stem cells
(CSCs) grown as adherent cultures in neurobasal medium on laminin-coated plates.
Glioma CSCs have markedly enhanced tumor-initiating activity when compared to the
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glioma monolayers from which they were derived. These adherent glioma CSCs share
many properties with CSCs grown as traditional tumorspheres. Interestingly adherent
glioma CSCs show constitutive activation of the STAT3/NF-κB signaling pathway and
upregulation of STAT3- and NF-κB-dependent genes. Gene expression profiling also
identified components of the Notch pathway as being deregulated in glioma CSCs, and
the deregulated expression of these genes was sensitive to treatment with STAT3
inhibitors. This finding is particularly important because Notch signaling appears to play
a key role in CSCs in a variety of cancers, and controls cell fate determination, survival,
proliferation and the maintenance of stem cells [84].
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CHAPTER 3. DISTINCT CANCER STEM CELL POPULATIONS PROMOTE
TUMOR HETEROGENEITY AND DETERMINE THE MOLECULAR
SIGNATURE OF GLIOBLASTOMA
Introduction
Although glioblastoma patients present uniform histological phenotypes, the
molecular determinants of the disease vary considerably between individual cases.
Genomic profiling of GBM samples in the TCGA database has identified four subtypes
of GBM based on robust gene expression, which may develop as a result of different
cancer stem cells driving tumorigenesis. Since few biomarkers show prognostic promise
or predict therapeutic response in GBM, improved molecular understanding of the tumor
initiating cells that drive cancer heterogeneity will advance treatment strategies for the
distinct molecular subclasses of GBM. In the present study, we identify two stem cell
populations that produce Classical or Mesenchymal GBM tumors but display identical
histological features. Gene expression analysis revealed that GBM xenografts derived
from tumorsphere cultured glioma CSCs produced a Classical GBM phenotype like that
of the bulk tumor cells, while adherent CSCs retained a Mesenchymal gene signature in
vitro and in vivo. Adherent GBM stem cell-derived xenografts also exhibited high STAT3
and ANGPTL4 expression levels compared to Classical tumors. This subpopulation of
glioma CSCs formed tumors with histopathological features of GBM and is enriched for
stem cell markers, transcriptional networks and pro-angiogenic markers characteristic of
the Mesenchymal subtype. These results were verified in subcutaneous and intracranial
tumors, and confirm the existence of multiple tumor initiating cell populations within
GBM. Taken together, establishing a CSC culture that maintains a Mesenchymal GBM
subtype provides a valuable and accurate model of the human disease, which will give
insight into the role in tumor progression of novel genes, such as STAT3 and ANGPTL4,
as well as their utility as new therapeutic targets.
Methods
Cell Culture
The human GBM6 patient-derived xenograft (PDX) of adult GBM tissue was
provided by Dr. C. David James, (Department of Neurological Surgery, University of
California, San Francisco) and continuously maintained as subcutaneous xenografts in
NSG mice. Monolayer and CSC cultures of GBM6 cells were derived from freshly
harvested tumor tissue. Short-term GBM6 xenolines were grown as monolayer cultures in
DMEM (Cellgro, Hemdon, VA) supplemented with 10% heat-inactivated fetal bovine
serum (Hyclone Labs, Thermo Scientific, Rockford, IL), 100 units/mL penicillin and 100
μg/mL streptomycin. Adherent and spheroid glioma CSCs were maintained in
NeuroBasal-A medium (Invitrogen, Carlsbad, CA) containing 2% B27 supplement, 2
mM L-glutamine, 100 units/mL penicillin, 100 μg/mL streptomycin, EGF (20 ng/ml),
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and basic FGF (40 ng/ml). For isolation of adherent CSCs, culture flasks were coated
with 100 μg/mL poly D-lysine (Sigma-Aldrich, St. Louis, MO) for 1 hr followed by
coating with 10 μg/mL laminin (Gibco, Life Technologies Inc., Grand Island NY) for 2
hr prior to use. Adherent CSCs were plated at 1 X 105 cells per 75 cm2 flask, grown to
confluence, dissociated with HyQTase (Thermo Scientific, Scientific, Rockford, IL), and
split at a 1:3 ratio. For isolation of spheroid CSCs, glioma cells were dissociated with
HyQtase and plated at ~ 1 x 105 cells/mL in ultra-low adhesion flasks.
Subcutaneous Xenografts
Animal experiments were performed in accordance with a study protocol
approved by the Institutional Animal Care and Use Committee of the University of
Tennessee Health Science Center. Glioma cancer xenografts were established in
five-week-old male NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice (Jackson Laboratory,
Bar Harbor, ME) by direct flank injection of 1×106 GBM6 cells transduced with
luciferase lentivirus constructs. For bioluminescence imaging, mice were injected
intraperitoneally with d-luciferin, imaged on the IVIS in vivo imaging system (Caliper
Life Sciences, Hopkinton, MA), and photonic emissions assessed using Living image®
software.
Orthotopic Injections
Animal studies were performed under established guidelines and supervision by
the St. Jude Children’s Research Hospital’s Institutional Animal Care and Use
Committee, as required by the United States Animal Welfare Act and the National
Institutes of Health’s policy to ensure proper care and use of laboratory animals for
research. Anesthetized animals (ketamine/xylazine) were placed on stereotactic
equipment where the scalp was prepped using alcohol and iodine swabs and artificial tear
gel applied to the eyes. Following scalp excision, a rectangular window was carved out
and the dura was completely removed from the surface of the brain, and 1x106 cells
suspended in 10 uL of media were injected approximately 2.5 mm deep in the right motor
cortex. The excision was closed with skin glue, and all animals were monitored closely
24 hrs post-operatively. For bioluminescence imaging, mice were injected
intraperitoneally with d-luciferin, imaged on the IVIS in vivo imaging system (Caliper
Life Sciences, Hopkinton, MA), and photonic emissions assessed using Living image®
software.
Gene Expression Analysis
Total RNA was isolated by treating tissue homogenates with Trizol followed by
isolation with the RNeasy Mini kit (Qiagen Inc., Valencia, CA). Samples were submitted
for complete mRNA expression profiling to the UTHSC Center of Genomics and
Bioinformatics (Memphis, TN) for labeling and hybridization to Human-HT12
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BeadChips (Illumina Inc.). Gene expression was also measured on the nCounter Analysis
System (Nanostring Technologies, Seattle, WA) using the panel of 230 human
cancer-related genes. In brief, total RNA was mixed with pairs of capture and reporter
probes, hybridized on the nCounter Prep Station, and purified complexes were measured
on the nCounter digital analyzer. To account for differences in hybridization and
purification, data was normalized to the average counts for all control spikes in each
sample and analyzed with nSolver software. Gene expression analysis was performed in
collaboration with Dr. David Finkelstein in the Division of Research Informatics at St.
Jude Children’s Research Hospital. Gene expression patterns were compared by principal
component analysis. Statistically significant genes were then identified by volcano plot,
which is a scatter-plot used to quickly identify changes in large datasets composed of
replicate data. It plots significance versus fold-change on the y- and x-axes, respectively.
Bonferroni correction was also used to calculate an adjusted probability of
comparison-wise type I error from the desired probability of family-wise type I error.
Ingenuity Pathway Analysis (IPA)
IPA (Qiagen Inc., Valencia, CA was used to identify canonical signaling
pathways and functional pathways as well as to produce networks of related genes
derived from genes changed in the analyzed comparisons. Here, the
rank-product-generated gene lists using a 50% false discovery rate were uploaded into the
IPA server as input data. IPA uses pathway libraries derived from the scientific literature.
Statistics for functional analysis were carried out by Fischer’s exact test (as done
automatically by the software).
Histopathology
Tissue derived from bulk tumor cells, adherent CSCs and tumorspheres (four
separate tumors for each condition) were fixed in 10% neutral buffered formalin for 24
hours, embed in paraffin, and sectioned at 5um thickness. For each sample, sections were
stained using a standard hematoxylin and eosin (H&E) protocol, or for the common GBM
neural markers GFAP, S100, OLIG2, MAP2 and the neuronal marker SYN. Sections
were analyzed by Dr. David Ellison at St. Jude Children’s Research Hospital.
Representative images of each sample/stain combination was captured at 20x original
magnification on a Nikon S1 digital camera.
Quantitative RT-PCR
Gene expression of RNA used for microarray analysis was measured by q-PCR
on an iCyclerIQ (Bio-Rad Laboratories, Richmond, CA) using an iScript One-Step
RT-PCR kit with SYBR Green (Bio-Rad Laboratories, Richmond, CA). Reaction
parameters were as follows: cDNA synthesis at 50°C for 20 min, transcriptase
inactivation at 95°C for 5 min, PCR cycling at 95°C for 10 sec, and 60°C for 30 sec for
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40 cycles. The following primers were used for RT-PCR: β-actin
5’-AGAAGGAGATCACTGCCCTG-3͛ (forward),
5’-CACATCTGCTGGAAGGTGGA-3͛ (reverse); CHI31
5’-GTGAAGGCGTCTCAAACAGG-3’ (forward),
5’-GAAGCGGTCAAGGGCATCT-3’ (reverse); TRADD
5’-GCTGTTTGAGTTGCATCCTAGC-3’ (forward),
5’-CCGCACTTCAGATTTCGCA-3’ (reverse); NF1
5’-AGATGAAACGATGCTGGTCAAA-3’ (forward),
5-CCTGTAACCTGGTAGAAATGCGA-3’ (reverse); RelB
5’-CAGCCTCGTGGGGAAAGAC-3’ (forward),
5’-GCCCAGGTTGTTAAAACTGTGC-3’ (reverse); CASP4
5’-TTTCTGCTCTTCAACGCCACA-3’ (forward),
5’-AGCTTTGGCCCTTGGAGTTTC-3’ (reverse); FGFR3
5’-TGCGTCGTGGAGAACAAGTTT-3’ (forward),
5’-GCACGGTAACGTAGGGTGTG-3’ (reverse); PDGFA
5’-GCAAGACCAGGACGGTCATTT-3’ (forward),
5’-GGCACTTGACACTGCTCGT-3’ (reverse); EGFR
5’-CTACGGGCCAGGAAATGAGAG-3’ (forward),
5’-TGACGGCAGAAGAGAAGGGA-3’ (reverse); AKT2
5’-ACCACAGTCATCGAGAGGACC-3’ (forward),
5’-GGAGCCACACTTGTAGTCCA-3’ (reverse); Nestin
5’-GGCGCACCTCAAGATGTCC-3’ (forward), 5’- CTTGGGGTCCTGAAAGCTG-3’
(reverse).
Statistical Analysis
At least three independent experiments were performed in duplicate, and data are
presented as means ± sd. ANOVA and post-hoc least significant difference analysis or
Student t tests were performed. p values < 0.05 (*) were considered statistically
significant.
Results
Diverse Molecular Signatures Found in GBM Cells and Subcutaneous Xenografts
Glioblastoma is characterized by extensive heterogeneity at the cellular and
molecular levels [145]. Our previous findings revealed upregulation of the STAT3,
NF-κB and Notch signaling pathways within GBM stem cells, so we then molecularly
characterized xenograft tumors formed by GBM bulk tumor cells and CSCs. In brief, we
prepared RNA from biological replicates of GBM6 cells grown as monolayers, adherent
CSCs, and tumorspheres as well as tumor tissue derived from each condition and
performed gene expression analysis. We concentrated our studies on genes analyzed in
the TCGA database, which contains mRNA expression profiles from large-scale
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multi-dimensional analysis of human GBM biospecimens [146]. We found that in vitro
the bulk tumor cells have a different molecular signature compared to cells grown under
both CSC conditions. In contrast, the tumors formed from the tumorsphere and adherent
CSCs showed distinct differences in gene expression pattern as shown in Figure 3-1A.
Most interesting, tumors that arose from bulk tumor cells and turmorspheres had similar
expression profiles while tumors that arose from adherent CSCs had a markedly different
expression profile. We then examined the mathematical variance among the data samples
by PCA mapping. Figure 3-1B shows that bulk tumor cells and tumors that arose from
them are relatively similar in expression profiles as well as adherent CSCs and their
derived tumors. However, the expression profile of tumorsphere samples is very
different. While the gene expression of spheroid cells is similar to adherent CSC samples,
the molecular signature of the tumor tissue that arose from these CSCs is completely
different. These results suggest that distinct stem cell populations exist and promote
tumor heterogeneity during GBM tumor initiation and progression.
Distinct Stem Cell Populations Drive GBM Molecular Subclassification
Genomic profiling has identified four subtypes of GBM based on patterns of gene
expression: Proneural, Neural, Classical and Mesenchymal. Heterogeneity of GBM
tumors is thought to be attributed to different causes or cells of origin [120]. To
determine if the distinct molecular signatures found between tumors derived from GBM
stem cells grown as adherent CSCs or tumorspheres corresponds to a specific subtype of
GBM, we analyzed “core” genes of each subtype that have been defined previously.
Verhaak and colleagues performed microarray analysis on two hundred GBMs and two
normal samples from the TCGA database and applied hierarchical clustering to assess
subclass cross validation error and find gene signatures for each class of GBM. We used
this information to categorize the genes within our array by their association with the
Classical, Neural, Proneural or Mesenchymal subclass. The PCA maps in Figure 3-2A
reveal how GBM bulk tumor cells, CSCs and the subsequent tumor tissue correspond to
the four subtypes of GBM. The distinct gene signatures among GBM tumor tissue (202
samples) from Classical (in white), Neural (in black), Proneural (in blue) and
Mesenchymal (in gray) subclasses is represented and matched to our samples. In vitro,
the gene expression profile of adherent CSCs (red) and tumorspheres (yellow) associate
with the Mesenchymal type of GBM, while the expression profile of bulk tumor cells
(orange) fall within the Classical subtype. The different gene signatures observed
between tumors derived from adherent CSCs and tumorspheres is also shown in
association with the GBM subclasses. While the adherent CSC-derived tumors maintain a
Mesenchymal gene signature, tumorspheres form tumors of a Classical subtype that
mimics the gene signature of tumors derived from bulk tumor cells.
To further illustrate the molecular subclassification of our GBM xenografts, we
measured some of the classic genes used to define the Classical and Mesenchymal GBM
subtypes by qPCR. In brief, RNA was extracted and pooled from 3 individual
subcutaneous tumors derived from monolayers, adherent CSCs or tumorspheres. As
shown in Figure 3-2B, the Mesenchymal markers CHI3L1, TRADD and RelB are
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Figure 3-1.

Illumina array analysis of GBM6 cells and tumor tissue.

RNA was prepared from GBM6 monolayer, adherent CSC, and tumorsphere cell cultures
as well as from subcutaneous tumors derived from each condition. Biological duplicates
were ran for each sample and data was collected and analyzed. A. Gene expression was
measured by Illumina array and genes reported in the TCGA database were analyzed. B.
The PCA plot represents the comparison of gene signatures from each condition.
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Figure 3-2.

Molecular classification of GBM6 cells and tissue.

A. Array analysis was performed and compared to GBM molecular subclasses; PCA map
depicts the classical, mesenchymal, neural, and proneural gene signatures and the gene
signature of GBM6 cells and tumor tissue derived from glioma monolayer, adherent
CSC, and spheroid cells. B. RNA was pooled from three individual tumor tissues derived
from GBM6 bulk tumor cells, adherent CSCs, and tumorspheres to determine gene
expression of molecular markers of GBM. Mesenchymal (CHI3L1, TRADD, NF1, RelB
& Caspase-4) and Classical genes (FGFR3, PDGFA, EGFR, AKT2 & Nestin) were
measured by qPCR and normalized to actin expression (n=3).
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significantly elevated in tissue derived from adherent CSCs compared to the other
tumors, and NF1, which is a tumor suppressor commonly downregulated in
Mesenchymal GBM, is decreased. The mesenchymal marker CHI3L1 in combination
with astrocytic markers is indicative of an epithelial-to-mesenchymal transition that has
been linked to aggressive, dedifferentiated tumors [124]. Genes in the TNF and NF-κB
pathways, such as TRADD and RelB, are highly expressed in this subtype as well,
potentially as a consequence of increased necrosis and associated inflammatory infiltrates
[127]. We also found that Classical markers PDGFA, EGFR, AKT and Nestin are highly
expressed in tumor tissue derived from bulk tumor cells and tumorspheres, while there is
relatively low expression in adherent CSC tumors. Most notably, EGFR and Nestin
expression are almost non-existent. Significant EGFR amplification is observed in 97%
of Classical GBMs in the TCGA database and infrequently in other subtypes along with
the neural precursor and stem cell marker, Nestin. This finding is of significant
importance as the GBM6 patient xenograft is from a patient with overexpression of the
VIII mutant of EGFR, and consistent with our finding of high EGFR expression in bulk
tumor cells and in tumors derived from them. These studies indicate that GBM stem cells
maintained in adherent culture conditions are a different tumor initiating subpopulation
than that of traditional tumorspheres. The adherent GBM CSCs exhibit a mesenchymal
gene signature and promote the initiation and progression of the Mesenchymal GBM
subtype in vivo.
Indistinguishable Histopathology among Heterogeneous GBM Xenografts
While GBM tumors represent different molecular subtypes, there is commonly no
distinction in histologic phenotype, which complicates the prognosis and treatment of this
malignancy [147]. The molecular heterogeneity observed in our GBM xenografts derived
from bulk tumor cells, adherent CSCs and tumorspheres lead us to examine the
histopathology of these tumors. Four individual subcutaneous tumors derived from each
cell culture condition were formalin-fixed, paraffin-embedded, and sectioned. Each
sample was stained for H&E analysis, and immunohistochemistry was performed to
measure immunoreactivity with antibodies for the common GBM markers GFAP, S100,
OLIG2, MAP2 and SYN. As shown in Figure 3-3A, the Classical GBM tumors derived
from bulk tumor cells and tumorspheres and the Mesenchymal tumors derived from
adherent GBM stem cells were all determined to be high-grade gliomas and
morphologically indistinguishable. Tumor cells with a high nuclear:cytoplasmic ratio and
little nuclear pleomorphism showed the morphology of relatively undifferentiated
high-grade gliomas. Neural markers used in glioma classification were also analyzed and
found to be indistinguishable among the molecularly heterogeneous GBM xenografts
(Figure 3-3B). There was strong immunoreactivity for GFAP and OLIG2 in many tumor
cells, while all tumor cells expressed S-100 and MAP-2. In neural tumors, GFAP,
OLIG-2 and MAP-2 are generally expressed by gliomas, while the neuronal marker
Synaptophysin is negative [148-151]. These findings reveal the similarity at the
microscopic level between the molecularly distinct xenografts of the Classical and
Mesenchymal subclasses derived from bulk tumor cells and adherent CSCs, respectively.
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Figure 3-3.

Pathological review of GBM6 tumor xenografts.

Cells from monolayer and adherent CSC culture conditions were injected subcutaneously
and allowed to grow to a diameter of ~400mm3. Tumors were extracted and paraffin
embedded for histology services. A. H&E staining as well as B. immunoreactivity of the
markers GFAP, S100, OLIG2, MAP2, and SYN was carried out and reviewed by Dr.
David Ellison at SJCRH. Tumor cells with a high nuclear:cytoplasmic ratio and little
nuclear pleomorphism showed the morphology of relatively undifferentiated high-grade
gliomas. There was strong immunoreactivity for GFAP or OLIG2 in many tumor cells,
while all tumor cells expressed S-100 and MAP-2. (All photomicrographs taken at 200x)
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It also demonstrates the importance of integrative histological and molecular
classification of gliomas in establishing effective treatment regimens for GBM patients.
Adherent CSCs Promote Mesenchymal Signature in Intracranial GBMs
In order to understand the role of the “true” tumor microenvironment on gene
expression in GBM we then performed our analysis in an orthotopic animal model by
intracranial injection of tumor cells. The human glioblastoma orthotopic mouse model
results in invasive growth in mice and allows users to quantitate intracranial tumor
growth [152]. To determine if our findings were also observed in the conventional
microenvironment of GBM, we performed intracranial injections of 1 x 106
luciferase-expressing GBM6 cells grown as short-term monolayer cultures, adherent
CSCs or tumorspheres. We first compared the tumor initiating capacity of the GBM bulk
tumor cells to both CSC conditions by bioluminescence imaging. As shown in Figure
3-4A, both CSC subpopulations formed tumors more rapidly than bulk tumor cells, and
survival was shorter in the more aggressive tumors. This is consistent with our previous
subcutaneous studies that revealed adherent CSCs were nearly 100-times more potent in
inducing tumors than the glioma monolayer cultures.
We next examined the histological phenotypes and molecular heterogeneity of the
different intracranial GBM xenografts. As shown in Figure 3-4B, the GBM tumors
derived from bulk tumor cells, adherent CSCs and tumorspheres were all determined to
be High-Grade Glioma and exhibit no distinction in H&E staining as before. All of the
tissue displayed characteristics of GBM, such as hypercellularity, atypical nuclei,
pseudopalisading necrosis and microvascular proliferation [153]. The traditional GBM
prognostic markers GFAP, S100, OLIG2, MAP2 and SYN were also analyzed and found
to be indistinguishable among the GBM xenografts.
To further refine the molecular subclassification of the intracranial GBM
xenografts, we measured the expression of genes used commonly to define the Classical
and Mesenchymal GBM subtypes by qPCR. In brief, RNA was extracted from 3
individual intracranial tumors derived from monolayers, adherent CSCs or tumorspheres.
As shown in Figure 3-4C, the Mesenchymal markers CHI3L1, TRADD, RelB and
Caspaase4 are significantly elevated in intracranial tumors derived from adherent CSCs
compared to the other xenografts, while NF1 is decreased. We also found that the
Classical markers FGFR3, PDGFA, EGFR, AKT-2 and Nestin are highly expressed in
tumor tissue derived from bulk tumor cells and tumorspheres, while there is little
expression in adherent CSC tumors. These orthotopic studies support our previous
finding that GBM stem cells maintained in adherent culture conditions are a different
tumor initiating subpopulation than that of traditional tumorspheres. The adherent GBM
CSCs exhibit a mesenchymal gene signature and promote the initiation and progression
of the Mesenchymal GBM subtype in vivo.
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Figure 3-4.

Characterization of orthotopic GBM6 tumors
6

A. NSG mice were orthotopically injected with 1x10 luciferase-tagged GBM6 cells
grown as monolayers, adherent CSCs or tumorspheres and tumor burden was measured
by Xenogen imaging twice a week (n=10 per group). B. Tumor-bearing brains were
extracted and paraffin embedded for histology services. H&E staining as well as analysis
of the markers GFAP, S100, OLIG2, MAP2, and SYN was carried out and reviewed by
Dr. David Ellison at SJCRH. C. RNA extracted from intracranial tumors was extracted
and submitted for array analysis. (n=3)
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Upregulation of STAT3 and ANGPTL4 in Mesenchymal GBM Xenografts
To identify specific genes differentially expressed in Mesenchymal GBM tumors
derived from adherent CSC cultures of GBM6 xenografts, we further analyzed the
mRNA expression profiling. The samples were also evaluated on the nCounter Analysis
System (Nanostring Technologies, Seattle, WA) using the human cancer-related panel of
230 genes. RNA was mixed with pairs of capture and reporter probes, hybridized on the
nCounter Prep Station, and purified complexes were measured on the nCounter digital
analyzer. To account for differences in hybridization and purification, data was
normalized to the average counts for all control spikes in each sample and analyzed with
nSolver software. Figure 3-5A reveals the different molecular signature observed
between bulk tumor cell and CSC-derived GBM tumors. Individual biological replicates
of tumor tissue showed little variation in gene expression, but there were clear differences
in the gene expression pattern in Classical and Mesenchymal tumors derived from
short-term monolayer cultures vs. adherent CSCs, respectively. Significant genes
upregulated or downregulated that passed the Bonferroni threshold in the adherent
CSC-derived tumors are shown in Figure 3-5B by Volcano Plot, with verified mRNA
levels of SPP1, ETV1, CCND2, CDH1, NQO1, STAT3 and LYN shown in Figure 3-5C.
Notably, the enhanced expression of STAT3 in Mesenchymal GBM6 tumors derived
from CSCs confirms in vitro results that we previously published [154]. One other report
has shown STAT3 to be an initiator and master regulator of mesenchymal transformation
in GBM [56]. Elevated expression of CDH1, NQO1 and LYN has also previously been
identified in GBM, with each contributing to the growth and invasion of this aggressive
brain tumor subtype in different ways [155-157].
Functional annotation of the genes differentially expressed in GBM tumors of the
Mesenchymal subclass formed from adherent CSCs also reveals that genes involved in
angiogenesis are significantly enriched (P<0.05, Ingenuity Pathway Analysis). The
schematic expression of these pro-angiogenic genes is shown in Figure 3-5D, and the
qPCR validation of ANGPTL4, IL8, CDKN2A and CXCL1 mRNA levels in adherent
CSC-derived tumors is shown in Figure 3-5E. Most interestingly, our lab has observed
the elevated expression of ANGPTL4 in xenografts derived from CSCs in other cancer
types [unpublished]. ANGPTL4 upregulation has also previously been identified in a
robust angiogenesis gene signature shown to correlate with the Mesenchymal subtype of
GBM [125]. The chemokine IL-8 has been found to be expressed and secreted at high
levels in GBM both in vitro and in vivo, and recent experiments suggest it is critical to
glial tumor neovascularity and progression [158]. Another chemokine, CXCL1, has been
implicated as an oncogenic factor in glioma and directly related to attenuated angiogenic
activity through NF-κB regulation [159]. These pro-angiogenic genes have been shown to
contribute to the vascularization of highly aggressive GBM tumors and therefore
represent therapeutic interests.
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Figure 3-5. Enrichment of pro-survival and pro-angiogenic genes in GBM tumor
tissue derived from adherent CSCs.
A. RNA was prepared from three separate tumors generated from GBM6 monolayer or
adherent CSCs and nanostring analysis was performed. B. Volcano plot depicting the
genes of interest within the CSC tumors that passed the Bonferroni test. C. Verification of
significant deregulated genes found in Nanostring analysis. The RNA used for Nanostring
analysis was prepared and the gene expression of SPP1, ETV1, CCND2, CDH1, NQO1,
and LYN was quantified by qPCR and normalized to actin expression. D. RNA was
prepared from tumor tissue derived from GBM6 bulk tumor cells and adherent CSCs to
perform microarray analysis; schematic representation of Ingenuity pathway analysis
showing the upregulation of genes involved in angiogenesis. E. qPCR validation of proangiogenic genes (ANGPTL4, IL8, CDKN2A and CXCL1) upregulated in GBM6
adherent CSC-derived tumor tissue normalized to actin expression (n=3).
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Figure 3-5.

Continued.
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Discussion
Although most glioblastoma multiforme (GBM) patients present uniform
histological phenotypes, the molecular determinants of disease aggressiveness vary
considerably between individual cases. The name “multiforme” is derived from the
histopathologic description of the varied morphologic features of this tumor and the
presence of heterogeneous cell populations within a single tumor, in which lesions with a
high degree of cellular and nuclear polymorphism and numerous giant cells coexist with
areas of high cellular uniformity [160]. Genomic profiling of GBM samples in the TCGA
database has identified four subtypes of GBM, Classical, Neural, Proneural and
Mesenchymal, based on robust gene expression, which are thought to develop as a result
of different cancer stem cells driving tumorigenesis [120]. Since few biomarkers show
prognostic promise or predict therapeutic response, improved molecular understanding of
the tumor initiating cells that drive cancer heterogeneity will advance treatment strategies
for the distinct molecular subclasses of GBM. In the present study, we demonstrate two
distinct stem cell populations that produce Classical or Mesenchymal GBM tumors but
display identical histological features.
We began our studies by performing microarray analysis to molecularly
characterize GBM bulk tumor cells, adherent CSCs and tumorspheres, as well as, the
tumors derived from each cell type. The results revealed that in vitro the bulk tumor cells
exhibited a different molecular signature compared to both CSC conditions, however the
tumor tissue displayed a distinct difference in gene expression pattern between the CSC
cultures. Our findings support recent studies proposing that tumor heterogeneity is a
result of cancer stem cells that are able to self-renew and generate differentiated progeny
that compose the bulk of the tumor. CSCs have been identified in several types of cancer,
including GBM. Initially, the expression of CD133 seemed to be the robust marker of
brain tumor stem cells. However, numerous studies have since shown that this marker
does not consistently distinguish tumorigenic and non-tumorigenic glioma cells,
suggesting that distinct CSC subpopulations exist to drive GBM tumorigenesis [161,
162]. To determine whether the two stem cell populations (adherent CSCs and
tumorspheres) we employed in our studies promote tumor heterogeneity corresponding to
a specific subtype of GBM, we analyzed traditional markers of the Classical, Neural,
Proneural and Mesenchymal subtypes. The different gene signatures observed between
tumors derived from adherent CSCs and tumorspheres were classified, and adherent
CSC-derived tumors were found to promote a Mesenchymal GBM gene signature, while
tumorspheres promoted the Classical GBM subtype like that of the bulk tumor cells.
These results were confirmed by qPCR and reveal that GBM stem cells maintained in
adherent culture conditions represent a different tumor initiating subpopulation than that
of traditional tumorspheres. The extensive heterogeneity at the cellular and molecular
levels of GBM that are found in tumors produced by CSCs has great significance for the
general outcome of the malignancy; it confounds our understanding of the disease and
also contributes to tumor aggressiveness and poses obstacles to the design of effective
therapies [163]. Therefore, establishing an adherent CSC culture method that exhibits a
mesenchymal gene signature and promotes the initiation and progression of the
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aggressive Mesenchymal GBM subtype in vivo, provides a valuable model of the human
disease for future studies.
Most GBMs are distinguished pathologically from low grade gliomas by the
presence of necrosis and microvascular hyperplasia, but there is no distinction between
molecular subtypes, which complicates prognosis and therapeutic strategies [164]. To
study the pathology of the Classical and Mesenchymal GBM tumors derived from our
different GBM6 cell cultures, each sample was stained for H&E analysis, and
immunohistochemistry was performed to review the common GBM markers GFAP,
S100, OLIG2, MAP2 and SYN. The Classical GBM tumors derived from bulk tumor
cells and tumorspheres and the Mesenchymal tumors derived from adherent GBM stem
cells were all diagnosed as high-grade glioma and displayed no differences in H&E
staining or marker expression. These findings reveal the pathological likeness between
the molecularly distinct Classical and Mesechymal xenografts derived from bulk tumor
cells and adherent CSCs, respectively. It also demonstrates the importance of integrative
histological and molecular classification of gliomas in establishing effective treatment
regimens for GBM patients
To determine if the molecular heterogeneity found in our High-Grade Glioma
xenografts is maintained in the conventional microenvironment of GBM, we performed
intracranial injections of GBM6 cells grown as short-term monolayers, adherent CSCs or
tumorspheres. The tumor initiating capacity of the GBM CSCs by intracranial injection
was comparable to our previous studies performed by subcutaneous injection. Both CSC
subpopulations formed tumors more rapidly than bulk tumor cells, and survival was
shorter in the more aggressive tumors [154]. We next examined the histological
phenotypes and molecular heterogeneity of the different intracranial GBM xenografts.
The GBM tumors derived from bulk tumor cells, adherent CSCs and tumorspheres were
all diagnosed as High-Grade Glioma and had no distinction in H&E staining or
traditional glioma markers as before. The common genes used to define the Classical and
Mesenchymal GBM subtypes were measured by qPCR, and the Mesenchymal markers
were significantly elevated in intracranial tumors derived from adherent CSCs compared
to the other xenografts, while NF1 was decreased. The Classical markers were also
highly expressed in tumor tissue derived from bulk tumor cells and tumorspheres, with
little expression in adherent CSC tumors. These orthotopic studies confirm our previous
finding that GBM stem cells maintained in adherent culture conditions represent a
different tumor-initiating subpopulation than that of traditional tumorspheres. The
adherent GBM CSCs exhibit a mesenchymal gene signature and promote the initiation
and progression of the Mesenchymal GBM subtype intracranially.
To identify novel genes specifically deregulated in Mesenchymal GBM tumors
derived from adherent CSC cultures of GBM6 xenografts, we re-analyzed our microarray
analysis on RNA prepared from GBM xenografts derived from bulk tumor cells, adherent
CSCs and tumorspheres and found that gene expression was markedly different between
GBM xenografts derived from these different cell populations. Most interestingly, the
expression of STAT3 was shown be elevated in the more aggressive stem cell-derived
tumors. This is consistent with our previous findings in vitro, in which we identified
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STAT3 as a potential therapeutic target due to its constitutive activation in GBM stem
cells [154]. STAT3 is a master regulator of genes involved in various steps of tumor
progression, so we sought to identify pathways that STAT3 could potentially regulate
within CSCs to promote gliomagenesis. IPA analysis revealed significant upregulation of
several genes involved in the angiogenic pathway, with ANGPTL4 being of great interest
since our lab has previously observed elevated expression of ANGPTL4 in xenografts
derived from CSCs in other cancer types [unpublished]. While previous reports suggest
EGFR induces ANGPTL4 expression and promotes tumor angiogenesis in malignant
gliomas, we find ANGPTL4 activation to be independent of EGFR upregulation in
Mesenchymal GBM xenografts [165]. The important roles of STAT3 and ANGPTL4 in
promoting GBM progression and vascularization represent potential therapeutic targets in
treating GBM and warrant further molecular characterization.
Summary
In conclusion, we performed gene expression profiling on subcutaneous
xenografts derived from GBM bulk tumor cells and two different stem cell cultures and
found distinct molecular signatures among the tissue. While monolayer and tumorsphere
cultured glioma cells produced a Classical GBM tumor, adherent CSCs retained the
Mesenchymal gene signature in vitro and in mouse xenografts. Mesenchymal GBM
xenografts derived from adherent CSCs also exhibited high STAT3 and ANGPTL4
expression levels compared to Classical tumors. This subpopulation of glioma cells
formed tumors with histopathological features of high-grade glioma and was enriched for
stem cell markers, transcriptional networks and angiogenesis markers. These results were
verified intracranially and confirm the existence of multiple tumor initiating cell
populations within GBM. Taken together, establishing a culture system that represents
the Mesenchymal GBM subtype provides a valuable and accurate model of the human
disease for future studies. The characterization of the Mesenchymal subclass will give
insight into novel genes, such as STAT3 and ANGPTL4, that are involved in glioma
tumor progression and lead to the discovery of new therapeutic targets in treating GBM.
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CHAPTER 4. STAT3 AND ANGPTL4 WORK TOGETHER IN CANCER STEM
CELLS TO DRIVE MESENCHYMAL GLIOBLASTOMA
Introduction
Despite multimodality therapeutic strategies developed over the past three
decades, patients with glioblastoma multiforme (GBM) still have a dismal prognosis and
overall survival time less than 14 months. The aggressiveness and rapid tumor relapse of
GBM is believed to be sustained by a cancer stem-like cell population that is able to
initiate and maintain tumors. Although CSCs represent only a small fraction of cells
within a tumor, their high tumor-initiating capacity and therapeutic resistance is believed
to drive tumorigenesis. Therefore, it is imperative to identify pathways associated with
CSCs in order to devise innovative strategies to selectively target them. In the present
study, we describe a novel relationship between STAT3 and ANGPTL4 within the cancer
stem-like cell population of GBM that drives tumor initiation and progression. Molecular
characterization of aggressive Mesenchymal GBM xenografts identified high STAT3 and
ANGPTL4 expression levels within the CD133+ CSC subpopulation, and these proteins
were shown to colocalize within GBM stem cells. Elevated STAT3 and ANGPTL4
expression was found to correlate to short-term survival of human GBM patients, and a
link in expression levels was observed between the genes in individual patient samples.
The deregulated expression of these genes in glioma CSCs was sensitive to the kinase
inhibitors, WP1066 and Sorafenib. Targeted inhibition of STAT3 and ANGPTL4 was
found to decrease stem cell marker expression within tumors and lead to tumor
regression. Taken together, we have identified an important relationship between STAT3
and ANGPTL4 in GBM stem cells, as well as potential therapeutic value as biomarkers
in targeting the CSC subpopulation of Mesenchymal GBM.
Methods
Tumor Studies in Mice
All animal experiments were performed in accordance with a study protocol
approved by the Institutional Animal Care and Use Committee of the University of
Tennessee Health Science Center. Glioma cancer xenografts were established in
five-week-old male NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice (Jackson Laboratory,
Bar Harbor, ME) by direct flank injection of 1×106 GBM6 cells transduced with
luciferase lentivirus constructs. For gene expression analysis, tumors were measured
bi-weekly until reaching a volume of ~400mm3; mice were then sacrificed and tumors
harvested for RNA. For bioluminescence imaging, mice were injected intraperitoneally
with d-luciferin, imaged on the IVIS in vivo imaging system (Caliper Life Sciences,
Hopkinton, MA), and photonic emissions assessed using Living image® software. At ~7
days after cell injection, when tumors formed in all mice, mice were given intraperitoneal
injections of WP1066 (44 mg/kg) and Sorafenib (20 mg/kg) in 1% DMSO every other
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day. For survival analysis mice were observed daily after injection and were sacrificed at
the first sign of shortness of breath, decreased locomotion or reduced body weight (>20%
of total body weight). Tumors were measured weekly with a handheld caliper and by
bioluminescence imaging. At the end of treatment the animals were sacrificed, and the
tumors were removed, weighed and processed for further study.
Quantitative RT-PCR
Total RNA was extracted as described before for xenografts; RNA was also
extracted from curls of formalin fixed paraffin-embedded tissue blocks of brain biopsy
specimens from GBM patients obtained from UTHSC Pathology Tissue Core using
RecoverAll Total Nucleic Acid Isolation Kit (Ambion Inc., Austin, TX). Gene expression
was measured by RT-PCR performed on an iCyclerIQ (Bio-Rad Laboratories, Richmond,
CA) using an iScript One-Step RT-PCR kit with SYBR Green (Bio-Rad Laboratories,
Richmond, CA). Reaction parameters were as follows: cDNA synthesis at 50°C for 20
min, transcriptase inactivation at 95°C for 5 min, PCR cycling at 95°C for 10 sec and
60°C for 30 sec for 40 cycles. The following primers were used for RT-PCR: β-actin
5-AGAAGGAGATCACTGCCCTG-3′ (forward), 5-CACATCTGCTGGAAGGTGGA-3′
(reverse); SPP1 5’-CTCCATTGACTCGAACGACTC-3’ (forward),
5’-CAGGTCTGCGAAACTTCTTAGAT-3’ (reverse); ETV1
5’-TACCCCATGGACCACAGATT-3’ (forward),
5’-CACTGGGTCGTGGTACTCCT-3’ (reverse); CCND2
5’-ACCTTCCGCAGTGCTCCTA-3’ (forward), 5’-CCCAGCCAAGAAACGGTCC-3’
(reverse); CDH1 5’-CGAGAGCTACACGTTCACGG-3’ (forward),
5’-GGGTGTCGAGGGAAAAATAGG-3’ (reverse); NQO1
5’-GAAGAGCACTGATCGTACTGGC-3’ (forward),
5’-GGATACTGAAAGTTCGCAGGG-3’ (reverse); STAT3
5’-CAGCAGCTTGACACACGGTA-3’ (forward),
5’-GCCCAATCTTGACTCTCAATCC-3’ (reverse); LYN
5’-GCTTTTGGCACCAGGAAATAGC-3’ (forward),
5’-TCATGTCGCTGATACAGGGAA-3’ (reverse); ANGPTL4
5’-GGCTCAGTGGACTTCAACCG-3’ (forward),
5’-CCGTGATGCTATGCACCTTCT-3’ (reverse); IL8
5’-TAGCAAAATTGAGGCCAAGG-3’ (forward),
5’-AGCAGACTAGGGTTGCCAGA-3’ (reverse); CDKN2A
5’-GGGTTTTCGTGGTTCACATCC-3’ (forward),
5’-CTAGACGCTGGCTCCTCAGTA-3’ (reverse); CXCL1
5’-ATGAGTGTGAAGGGCATGGGC-3’ (forward),
5’-TCACTGCTTTTACCCCAGGG-3’ (reverse); VEGFR-1
5’-TTTGCCTGAAATGGTGAGTAAGG-3’ (forward),
5’-TGGTTTGCTTGAGCTGTGTTC-3’ (reverse); VEGFR-2
5’-GGCCCAATAATCAGAGTGGCA-3’ (forward),
5’-CCAGTGTCATTTCCGATCACTTT-3’ (reverse); CD133
5’-CATCCACAGATGCTCCTAAGG-3’ (forward),
5’-AAGAGAATGCCAATGGGTCCA-3’ (reverse); SOX2
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5′-GCCGAGTGGAAACTTTTGTCG-3′ (forward),
5′-GCAGCGTGTACTTATCCTTCTT-3′ (reverse); Nestin
5’-GGCGCACCTCAAGATGTCC-3’ (forward), 5’-CTTGGGGTCCTGAAAGCTG-3’
(reverse)
Immunofluorescence and Confocal Microscopy
Tissue was embedded in OCT compound and cryosectioned at 10 Pm prior to
fixation with 4% paraformaldehyde and blocking with 5% BSA. Tissue was incubated
with antibodies directed against STAT3 (Cell Signaling Technology, Beverly, MA) and
ANGPTL4 (Invitrogen, Carlsbad, CA), and subsequently stained with goat anti-mouse
Alexa Fluor 488 and goat anti-rabbit Alexa Fluor 555 (Invitrogen, Carlsbad, CA).
Sections were counterstained with Vectashield mounting media with DAPI (Vector
Laboratories, Burlingame, CA). Cells were grown in 8-well chamber slides (Millipore
Co., Bedford, MA) to ~50% confluence. The cells were then washed with PBS, fixed
with 4% paraformaldehyde and methanol, and permeabilized with 1% Triton X-100.
After blocking with 5% goat serum, cells were stained as described above. Images were
captured on a Zeiss LSM700 laser scanning confocal microscope (Zeiss, New York, NY).
Tumor Digestion and Flow Sorting
All glioma tumors used for flow-sorting experiments were harvested from NSG
mice when they reached a size of ~400 mm3. Tumor tissue was chopped finely with razor
blades and the resultant cell suspension was passed through a 40μm filter insert. Cells
were washed with dPBS and resuspended in DMEM containing 10% FBS. The
percentage of human CD133 cells was determined using antibodies labeled with either
fluoresceinisothiocyanate (FITC) or phycoerythrin (PE). The anti-CD133 antibody
conjugated to PE (clone: AC133/2 (293C3)) was obtained from (Miltenyi-Biotec,
Bergisch Gladbach, Germany). Clone AC133/2 (293C3) recognizes epitope 2 and does
not overlap with clone AC133 used in the selection. Flow cytometric analysis was
performed using a LSR flow cytometer (BD Biosciences, San Jose, CA). Briefly, 10x106
cells were incubated with antibodies, and data acquisition and analysis was performed on
a three-laser LSR (Becton-Dickinson) flow cytometer using CellQuest software. Cells
negative for CD133 were placed in monolayer culture conditions, while CD133+ cells
were grown as adherent CSCs.
Cell Culture
The human GBM6 patient-derived xenograft (PDX) of adult GBM tissue was
provided by Dr. C. David James, (Department of Neurological Surgery, University of
California, San Francisco) and continuously maintained as subcutaneous xenografts in
NSG mice. Monolayer and CSC cultures of GBM6 cells were derived from freshly
harvested tumor tissue. Short-term GBM6 xenolines were grown as monolayer cultures in
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DMEM (Cellgro, Hemdon, VA) supplemented with 10% heat-inactivated fetal bovine
serum (Hyclone Labs, Thermo Scientific, Rockford, IL), 100 units/mL penicillin and 100
μg/mL streptomycin. Adherent and spheroid glioma CSCs were maintained in
NeuroBasal-A medium (Invitrogen, Carlsbad, CA) containing 2% B27 supplement, 2
mM L-glutamine, 100 units/mL penicillin, 100 μg/mL streptomycin, EGF (20 ng/ml),
and basic FGF (40 ng/ml). For isolation of adherent CSCs, culture flasks were coated
with 100 μg/mL poly D-lysine (Sigma-Aldrich, St. Louis, MO) for 1 hr followed by
coating with 10 μg/mL laminin (Gibco, Life Technologies Inc., Grand Island NY) for 2
hrs prior to use. Adherent CSCs were plated at 1 X 105 cells per 75 cm2 flask, grown to
confluence, dissociated with HyQTase (Thermo Scientific, Scientific, Rockford, IL), and
split at a 1:3 ratio. For isolation of spheroid CSCs, glioma cells were dissociated with
HyQtase and plated at ~ 1 x 105 cells/mL in ultra-low adhesion flasks.
Chromatin Immunoprecipitation
Chromatin Immunoprecipitation (ChIP) was carried out using the ChIP-ITTM
Express Enzymatic kit (Active Motif, Carlsbad, CA) according to the manufacturer's
instructions. In brief, chromatin from cells was cross-linked with 1% formaldehyde (10
min at 22oC), sheared to an average size of 200 bp with a Biorupter sonicator
(Diagenode, Sparta, NJ), and then immunoprecipitated with antibodies against STAT3
(Santa Cruz Biotechnology, Santa Cruz, CA). ChIP-PCR primers were designed to
amplify a proximal promoter region containing putative STAT3 (-1348 to -1369) binding
sites in the ANGPTL4 promoter. The primers used were: for STAT3 site,
5’-CATTAAAGACCCTGGCGGTA-3’ (forward),
5’-GGATCACAGTCGTGTGAGGA-3’ (reverse).
TCGA Data Analysis
To examine the relationship between STAT3 and ANGPTL4 expression in human
GBM brain tissue, we queried the TCGA data portal for all low-grade glioma and GBM
samples with gene expression (BI_HT_HG-U113A Array Data Set) data available as well
as accompanying clinical data. The data set was filtered for samples having expression
data for STAT3, ANGPTL4 and clinical data, yielding a final set of 265 individual lowgrade glioma samples and 328 independent GBM patient samples. The samples were then
grouped according to glioma grade and Karnofsky Performance Status, which takes into
account the patient performance in general daily life activities. The Karnofsky score runs
from 100 to 0, where 100 is defined as "perfect" health and 0 as death. Statistical analysis
was performed using Graphpad Prism.
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Apoptosis Assay
The induction of apoptosis was monitored by flow cytometry (Accuri Model 6C)
using the Annexin V-FITC apoptosis detection kit (BD Pharmingen, San Diego, CA),
according to the manufacturer's instructions.
WP1066 and Sorafenib Studies in vivo
1x106 GBM6 cells grown as monolayers or adherent CSCs were subcutaneously
injected in to the flanks of NSG mice, and animals were monitored for tumor growth
twice a week by caliper measurement. Upon induction of detectable tumors as
determined by caliper measurement, WP1066 (40 mg/kg) and Sorafenib (15 mg/kg) in
DMSO/Polyethylene gycol were delivered daily by intra-tumoral injection. The effect of
these drugs on tumor progression was measured by caliper measurement and Xenogen
live animal imaging.
Statistical Analysis
At least three independent experiments were performed in duplicate, and data are
presented as means ± sd. ANOVA and post-hoc least significant difference analysis or
Student t tests were performed. p values < 0.05 (*) were considered statistically
significant.
Results
Constitutive Activation of STAT3 and ANGPTL4 in the CSC Subpopulation of
Mesenchymal GBM Tumors
Aberrant activation of STAT3 and ANGPTL4 has been found to be associated
with tumor progression in blood malignancies and a variety of human solid tumors such
as breast, prostate, renal, and head and neck cancers [166-168]. Our previous studies
reveal the upregulation of these genes within Mesenchymal GBM xenografts. To
characterize the combined roles of STAT3 and ANGPTL4 in the CSC subpopulation of
Mesenchymal GBM tumors, we examined the intracellular localization of STAT3 and
ANGPTL4 by confocal microscopy. Mesenchymal GBM6 tumors derived from cells
grown as adherent glioma CSCs were sectioned and immunostained with antibodies
specific for STAT3 and ANGPTL4; cells were counterstained with DAPI to define
nuclear localization of proteins. As shown in Figure 4-1A, STAT3 and ANGPTL4 are
present in the cytoplasm and nucleus of various cells throughout Mesenchymal GBM
tissue, but their colocalization is only evident in the nucleus of a few cells. To determine
if the interaction of STAT3 and ANGPTL4 is specific to the CSC subpopulation of GBM
tumors, single cells were isolated from Mesenchymal xenografts and flow sorted by the
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Figure 4-1. Enhanced ANGPTL4 expression correlates with STAT3 activation in
the GBM CD133+ CSC subpopulation.
A. Tumor tissue derived from GBM6 adherent CSCs was sectioned and stained with
antibodies as indicated and analyzed by confocal microscopy. STAT3 is represented in
green, ANGPTL4 is represented in red, and nuclear DAPI staining in blue. White pixels
represent the colocalization of STAT3 and ANGPTl4 proteins within the tissue. B. Cells
were isolated from GBM6 xenografts and sorted for CD133+ and CD133- populations.
C. RNA was extracted from cells and STAT3 and ANGPTL4 gene expression levels
were measured by qPCR and normalized to actin. (n=3).
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stem cell marker CD133. Figure 4-1B displays the sorted CD133+ and CD133- cell
populations and reveals that 2% of cells within the Mesenchymal GBM xenografts are
CD133+ stem cells. Since studies have shown that CD133 does not consistently
distinguish tumorigenic and non-tumorigenic glioma cells [161, 162], CD133- cells were
placed in monolayer and adherent CSC culture conditions while CD133+ cells were
grown only as adherent CSCs. RNA was then prepared from bulk tumor cells, CD133stem cells and CD133+ stem cells and analyzed by qPCR for STAT3 and ANGPTL4
expression. As shown in Figure 4-1C, both STAT3 and ANGPTL4 are detectable in
glioma cells regardless of whether they are bulk tumor cells or CSCs. However,
activation of STAT3 and ANGPTL4 is markedly greater in CD133+ CSCs, suggesting
that the proteins are constitutively activated in glioma cells but exhibit increased activity
in the CD133+ CSC subpopulation of Mesenchymal GBM.
To further characterize the activation of STAT3 and ANGPTL4 in glioma CSCs
that promote the formation of Mesenchymal GBM tumors, GBM6 cells were grown in
vitro as monolayers or adherent CSCs on glass slides and immunostained with antibodies
for STAT3 and ANGPTL4 as above. As shown in Figure 4-2A, although STAT3 and
p65 are present in the cytoplasm and nucleus of both GBM6 bulk tumor cells and
adherent CSCs, their colocalization is only evident in the nucleus of adherent CSCs.
Since both STAT3 and ANGPTL4 may play important roles in CSC maintenance, we
next examined whether they interact. Examination of putative transcription binding sites
revealed three STAT3 binding sites proximal to the ANGPTL4 promoter. As shown in
Figure 4-2B, specific primers were designed and synthesized for each of these potential
binding sites in the ANGPTL4 promoter, and STAT3 binding was detected by ChIP
analysis for site-II. In brief, protein-DNA complexes were crosslinked with
formaldehyde, chromatin was sheared to average of 200bp and immunoprecipitated with
anti-STAT3, crosslinking reversed and the resulting DNA sequences detected by PCR
and qPCR. As shown in Figure 4-2C, significantly increased binding of STAT3 to the
ANGPTL4 promoter was observed in GBM adherent CSCs as compared to bulk tumor
cells. Also, the STAT3 inhibitor WP1066 is shown to decrease STAT3 binding to
ANGPTL4 in CSCs. Taken together, these results show that STAT3 regulates ANGPTL4
expression in adherent CSCs by directly binding to its promoter, and this interaction can
be blocked with targeted STAT3 inhibitors.
Additionally to confirm that ANGPTL4 is indeed important to GBM CSCs, other
GBM cell lines were analyzed for ANGPTL4 expression as well as members of the
VEGF signaling cascade, a known activator of ANGPTL4. qPCR was performed on
RNA extracted from GBM6, U87, SJG2 and MT330 monolayers and adherent CSCs. As
shown in Figure 4-2D, expression of ANGPTL4, VEGFR-1 and VEGFR-2 are
significantly upregulated in 3 out of the 4 adherent CSC cultures when compared to bulk
monolayers cultures of glioma cells, suggesting that ANGPTL4 alongside STAT3 could
play an important role in stem cell maintenance and subsequent GBM tumor initiation
and progression. While constitutively activated STAT3 has previously been found in
glioma CSCs and required for their proliferation and survival, the role of ANGPTL4 in
GBM stem cells is unknown and represents a highly novel finding. The upregulation of
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Figure 4-2.

Crosstalk between STAT3 and ANGPTL4 in CSCs.

A. GBM6 bulk tumor cells (Mono) and adherent CSC cultures were fixed and
immunostained with antibodies as indicated and analyzed by confocal microscopy;
STAT3 is represented in green, ANTPL4 is represented in red and nuclear DAPI staining
in blue. White pixels represent the colocalization of STAT3 and ANGPTL4 proteins
within the cells. B. STAT3 binding sites on ANGPTL4 promoter; site 2 was used for the
assay. C. ChIP analyses of STAT3 to Notch1 promoter; the ChIP-enriched DNA levels
analyzed by qPCR were normalized to input DNA, followed by subtraction of nonspecific binding determined by control IgG. D. Gene expression of the pro-angiogenic
genes ANGPTL4, VEGFR-1 and VEGFR-2 was measured by qPCR in GBM6, MT330,
U87 and SJG2 bulk tumor cells (mono) and adherent CSCs and normalized to actin
expression (n=3).
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ANGPTL4 in the tumor initiating subpopulation of Mesenchymal GBM is a novel
finding, and its biological relationship with STAT3 is of great therapeutic interest.
The Relationship between STAT3 and ANGPTL4 Expression to Glioma Grade and
Patient Performance Status in Clinical Specimens
To examine STAT3 and ANGPTL4 expression in human glioma, we analyzed
information in the TCGA database for the correlation between glioma grade and the
expression of STAT3 and ANGPTL4. Gene expression of STAT3 and ANGPTL4 was
examined in 10 normal brain samples, 265 individual low grade glioma patients and 328
individual GBM patients for comparison. As shown in Figure 4-3A, both STAT3 and
ANGPTL4 levels are significantly increased in GBM samples when compared to normal
tissue and even lower grade gliomas. We also analyzed GBM specimens in the TCGA
database to investigate the relationship between patient performance status and STAT3
and ANGPTL4 levels. The 328 GBM patients were placed into groups according to their
Karnofsky performance status, and their gene expression was compared to the 10 normal
brain samples. As shown in Figure 4-3B, the levels of ANGPTL4 are similar among
groups, while a significant increase in STAT3 expression was found in lower performing
patients when compared to those with good performance.
We then independently determined whether the expression of STAT3 and
ANGPTL4 correlates with patient survival. Brain biopsy specimens from 24 GBM
patients that represented long-term and short-term survival after diagnosis were obtained
from the UTHSC tissue core, and RNA was isolated from FFPE tissue blocks to
determine expression of STAT3 and ANGPTL4. As shown in Figure 4-3C, although
there was significant patient-to-patient variability as expected, there was a direct
relationship between STAT3 and ANGPTL4 expression and patient survival. A
statistically significant increase in STAT3 and ANGPTL4 gene expression was observed
in GBM patients that survived less than one year when compared to long-term survivors.
Interestingly, several patients exhibited elevated expression of both STAT3 and
ANGPTL4, while others were shown to have low levels of both genes. The direct
correlation of the expression of these genes in GBM is shown in Figure 4-3D. We next
looked at the potential of STAT3 and ANGPTL4 in predicting survival of GBM patients.
In Figure 4-3E we show that high levels of STAT3 significantly correlate with shortterm survival, while high ANGPTL4 levels appear to correlate with poor patient survival
but this was found to be not statistically significant.
The Effects of Specific STAT3 and VEGF Inhibitors on GBM CSCs
We next sought to determine the effect of STAT3 and VEGF inhibitors on the
intracellular localization of STAT3 and ANGPTL4 in GBM stem cells. Adherent GBM6
CSCs were plated on 8-well slides and treated for 2 hours with a pharmacological
inhibitor of STAT3 (25 PM WP1066) and/or VEGF inhibitor (5 PM Sorafenib), and then
immunostained for STAT3 and ANGPTL4. As shown in Figure 4-4A and previously in
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Figure 4-3.
samples.

Upregulation of STAT3 and ANGPTL4 expression in human GBM

A. Gene expression of STAT3 and ANGPTL4 was obtained from the TCGA database to
compare normal brain tissue (n=10), low grade glioma samples (n=265) and GBM
samples (n=328). B. Gene expression of STAT3 and ANGPTL4 was obtained from the
TCGA database for normal brain tissue (n=10) and GBM samples (n=328) to compere
levels based on patient performance. C. Human GBM tissue samples were obtained from
UTHSC Pathology and RNA was extracted; gene expression of STAT3 and ANGPTL4
was measured by qPCR and normalized to actin expression (n=12) to study correlation to
patient survival. D. Correlation of STAT3 and ANGPTL4 expression within human
GBM samples. E. Survival analysis of GBM patients expressing high or low STAT3 and
ANGPTL4.
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Figure 4-4.
CSCs.

Effects of selective STAT3 and VEGF inhibitors on adherent glioma

A. Cells were treated with vehicle, WP1066 (50 μM) and/or Sorafenib (5 μM) and
colocalization of STAT3 and ANGPTL4 was determined by immunostaining; RedAngptl4, Green-Stat3, Blue-DAPI, White-Colocalization. B. GBM6 Ad-CSCs were
treated with STAT3 (50uM WP1066) or VEGF (10uM Sorafenib) inhibitors for 6 hrs.
RNA was prepared and the gene expression of ANGPTL4, VEGF-R1, VEGF-R2,
CD133, SOX2 and Nestin was quantified by qPCR and normalized to actin expression
(n=3). C. Proliferation of GBM6 monolayer and adherent CSC cultures was measured by
MTT assay after treatment (72 hr) with WP1066 or Sorafenib at the indicated
concentrations. D. Apoptosis of GBM6 monolayer and adherent CSC cultures was
measured by AnnexinV staining after 48 hrs treatment with WP1066 (10uM) and/or
Sorafenib (5uM).
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Figure 4-4.

Continued.
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Figure 4-2A by confocal microscopy, STAT3 and ANGPTL4 are colocalized in the
nucleus of adherent CSCs. In contrast, treatment with WP1066 or Sorafenib markedly
inhibits the colocalization of STAT3 and ANGPTL4 within the nucleus of GBM6 glioma
CSCs. It is of interest that colocalization of STAT3 and ANPTL4 appears to be
specifically at the nuclear membrane of cells. Furthermore, the combined treatment with
these inhibitors prevents expression of STAT3 and ANPTL4, and results in a change in
cellular morphology, such as the cell shrinkage and lifting, that is indicative of cells
undergoing apoptosis.
To characterize the functional significance of blocking the STAT3 and ANGPTL4
pathways in CSCs, we examined the effects of WP1066 and Sorafenib treatment on the
expression of genes involved in angiogenesis as well as in stem cell maintenance. Figure
4-4B reveals the significantly decreased expression of pro-angiogenic genes (ANGPTL4,
VEGFR-1 and VEGFR-2) and stem cell markers (CD133, SOX2 and Nestin) upon
STAT3 and VEGF inhibition. Both WP1066 and Sorafenib treatment had similar
inhibitory effects on pro-angiogenic gene expression, but in combination had no greater
effects than each drug alone. This result suggests that inhibition of STAT3-regulated
ANGPTL4 is comparable to VEGF inhibition in GBM. In contrast, combined treatment
with WP1066 and Sorafenib was found to significantly decrease the expression of genes
associated with a stem cell signature in GBM6 cells.
We then examined the effects of WP1066 and Sorafenib on the cell viability in
glioma monolayer and adherent CSC cultures. Varying concentrations of both inhibitors
were tested by MTT assay and were found to induce a dose-dependent reduction in cell
number in both glioma monolayers and adherent CSCs, but there was a markedly
enhanced effect on adherent CSCs (Figure 4-4C). We then determined the effect of these
inhibitors on the induction of apoptosis in adherent CSCs as determined by flow
cytometry of Annexin V stained cells. In brief, cells in 6-well plates were treated with 10
PM WP1066, 5 PM Sorafenib or a combination of these inhibitors together for 48 hrs. As
shown in Figure 4-4D, although both inhibitors induced detectable apoptosis in glioma
adherent CSCs, there was a greater effect when these inhibitors were used in combination
on adherent CSCs.
Effect of Treatment with STAT3 and VEGF Inhibitors on Mesenchymal GBM
Tumor Progression
Since both STAT3 and ANGPTL4 have been associated with various steps of
tumor progression, we then examined the effects of STAT3 and ANGPTL4 inhibition on
Mesenchymal gliomagenesis. In brief, NSG mice were subcutaneously injected with
GBM6 cells maintained as monolayer or adherent CSC cultures, and tumor volume was
determined at weekly intervals by caliper measurement. At the first sign of tumor
formation at day 20, intraperitoneal drug delivery was done every other day for two
weeks using WP1066 (40 mg/kg) and Sorafenib (15 mg/kg). Figure 4-5A displays the
effect of both drugs on tumor progression measured by xenogen imaging. The formation
of GBM6 tumors was markedly suppressed by inhibition of STAT3 and ANGPTL4, with
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Figure 4-5

Efficacy of STAT3 and ANGPTL4 inhibitors in vivo.

Mice were subcutaneously injected with 1x106 luciferase-tagged GBM6 cells grown as
monolayers or adherent CSCs and upon first detection of tumor, mice were treated with
WP1066 (40mg/kg), Sorafenib (20mg/kg) or in combination every other day beginning
on day 21 after initial injection. A. Effect of drug treatment was measured by
bioluminescence twice a week (representive images shown for Day 31) and B. tumor
volume was measured twice a week by caliper measurement. (n=5 per condition)
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the combined treatment of WP1066 and Sorafenib completely ablating glioma
tumorigenesis. As shown in Figure 4-5B, tumor progression was dramatically decreased
following treatment with WP1066 and Sorafenib alone, and the drug combination led to
enhanced tumor regression. These results indicate the significance of elevated STAT3
and ANGPTL4 in GBM progression and the potential of selective STAT3 and ANGPTL4
inhibitors in targeting the CSC subpopulation of Mesenchymal GBM.
Discussion
Mesenchymal GBM is the most aggressive and deadly form of glioma, accounting
for around 30% of GBM cases. Despite improved molecular characterization, aggressive
surgery, radiation and chemotherapy, the median survival of patients remains only around
1 year. The ineffectiveness of current therapies may reflect the lack of potency on the
CSC subpopulation, which remains viable and commonly leads to tumor regeneration.
Although CSCs represent only a small population of cells within a tumor, their high
tumor-initiating capacity and therapeutic resistance may play a critical role in driving
GBM tumorigenesis. Therefore, it is imperative to identify biomarkers associated with
CSCs in order to devise strategies to selectively target them and subsequently block
GBM progression. In the present study, we describe a novel relationship between STAT3
and ANGPTL4 within the stem-like cell population of Mesenchymal GBM that drives
tumor initiation and progression.
We previously performed microarray analysis on RNA prepared from GBM
xenografts derived from bulk tumor cells and adherent CSCs and found elevated levels of
both STAT3 and ANGPTL4 in aggressive Mesenchymal tumors formed from CSCs.
These results are consistent with previous findings in Mesenchymal GBM, in which
STAT3 was suggested to be a major regulator of mesenchymal transformation [56]. A
robust angiogenesis gene signature, including ANGPTL4, has also been shown to
correlate with the Mesenchymal subtype of GBM [125]. ANGPTL4 is a secreted,
matricellular protein that provides signals to support many steps of tumor progression,
especially angiogenesis [109, 169]. While ANGPTL4 is commonly activated by VEGF or
HIF-1, studies have identified ANGPTL4 as being induced by constitutive activation of
STAT3 [114]. This led us to evaluate the relationship of these proteins within
Mesenchymal GBM CSCs. Constitutive activation of STAT3 and ANGPTL4 and their
direct interaction was evidenced by confocal microscopy in certain cells throughout
GBM xenografts, leading us to believe these cells represented the CSC subpopulation of
the tumor. Upon isolation of CD133+ cells from GBM xenografts, STAT3 and ANGPTL4
were shown to be dramatically activated in CSCs when compared to the CD133population. Furthermore, the colocalization of STAT3 and ANGPTL4 was also observed
in vitro in glioma adherent CSCs but not bulk tumor cells, indicating the importance of
STAT3 and ANGPTL4 to the CSC subpopulation of GBM. These results are supported by
recent studies, which have identified the requirement of STAT3 for CSC proliferation and
survival and the involvement of ANGPTL4 in maintenance of stem cell niches [80]. In
addition, we identified direct crosstalk between STAT3 and ANGPTL4 within GBM
CSCs by demonstrating the direct binding of STAT3 to the ANGPTL4 promoter. These
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results are consistent with previous findings in breast and renal cell carcinoma, in which
STAT3 was shown to activate ANGPTL4 by binding its promoter and interacting with
HIF-1 and other coactivators [115].
STAT3 has been shown to activate ANGPTL4 directly or indirectly through
transcriptional regulation of VEGF and HIF-1 in various human cancers, so we next
examined the relationship of STAT3 and ANGPTL4 expression in GBM to patient
prognosis and survival based on information in the TCGA database [27, 28]. High STAT3
and ANGPTL4 levels were observed in GBM samples when compared to normal brain
and lower grade gliomas, and enhanced expression also correlated to short-term survival.
Consistent with our findings, STAT3 is reported to be among the most frequently
activated oncogenic proteins in multiple solid tumor types. More specifically, a large
body of data has demonstrated activation of the typically quiescent STAT3 pathway as
being crucial to tumorigenesis and a predictor of poor prognosis in many malignancies
including gliomas [55]. ANGPTL4 has been identified as a prominent gene in in vivo
hypoxia gene sets that predict poor outcome in multiple tumor types. In a study of several
epithelial tumor types, ANGPTL4 levels increased as tumors progress from local to
metastatic disease [107, 108]. In our studies, we found a strong relationship between poor
patient performance and survival and enhanced expression of STAT3 and ANGPTL4 in
GBM patients. Additionally, our studies revealed that several individual patients
exhibited elevated expression of both STAT3 and ANGPTL4, while others were shown
to have low levels of both genes. A direct correlation in expression levels of STAT3 and
ANGPTL4 was found within human GBM samples. These results indicate that the
co-expression of STAT3 and ANGPTL4 may have diagnostic and prognostic utility in
GBM. Moreover, since ANGPTL4 is a secreted protein and detectable by ELISA, in
future studies ANGPTL4 levels could be measured for a non-invasive test of tumor
response and diagnosis.
Targeted small molecule inhibitors of STAT3 have previously been shown to
inhibit CSC proliferation and tumorsphere formation as well as sensitize GBM stem cells
to TMZ [81]. We examined the effects of the STAT3 inhibitor WP1066 and the indirect
ANGPTL4 inhibitor Sorafenib, which targets VEGF signaling, on glioma CSCs and
Mesenchymal GBM progression. WP1066 is a JAK-2 kinase inhibitor that blocks the
tyrosine phosphorylation of STAT3, which is the transcriptionally active form of STAT3.
It has been shown to have pro-apoptotic and anti-proliferative activity in a variety of
tumor types, including glioma, and most importantly shown to cross the blood brain
barrier [143, 170]. Sorafenib is a multitargeted tyrosine kinase inhibitor with antiangiogenic properties that works by inhibiting VEGFR activation. It has proven efficacy
for treatment of various cancers and is currently in clinical trials for GBM [171, 172]. In
our study, both drugs blocked the interaction of STAT3 and ANGPTL4 in GBM stem
cells and lead to a decrease in expression of pro-angiogenic genes as well as stem cell
marker genes, which suggest an important combined role of STAT3 and ANGPTL4 in
Mesenchymal GBM stem cell maintenance. In addition, combined treatment with
WP1066 and Sorafenib resulted in an induction of apoptosis in GBM CSCs. We also
studied the sensitivity of Mesenchymal GBM xenografts to these targeted drugs and
found that both WP1066 and Sorafenib decreased cancer progression individually, while
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combined treatment lead to complete tumor regression. The drugs have not been used in
combination previously, but our individual results are similar to previous studies done
with these inhibitors. WP1066 has been shown to significantly inhibit growth of
malignant glioma xenografts by blocking STAT3 activation and subsequent
pro-proliferative genes [170]. Interestingly, studies show that Sorafenib induced growth
arrest and apoptosis of GBM cells by blocking VEGF and STAT3 signaling [173]. Taken
together, we have identified a significant relationship between STAT3 and ANGPTL4 in
GBM stem cells and their therapeutic value as biomarkers in targeting the CSC
subpopulation of Mesenchymal GBM.
Summary
In conclusion, we characterized the molecular properties of Mesenchymal GBM
xenografts derived from cancer stem-like cells and identified biomarkers associated with
the CSC subpopulation of GBM. CD133+ cells isolated from tumor tissue expressed
elevated levels of both STAT3 and ANGPTL4, and these proteins were found to
colocalize within GBM stem cells. Aberrant STAT3 and ANGPTL4 expression was also
found to correlate to short-term survival of human GBM patients, and a link in expression
levels was observed between the genes in individual patient samples. The deregulated
expression of these genes in glioma CSCs was sensitive to targeted kinase inhibitors,
WP1066 and Sorafenib. Targeted therapy against STAT3 and ANGPTL4 was found to
decrease stem cell marker expression within tumors and lead to tumor regression. The
novel relationship between STAT3 and ANGPTL4 in Mesenchymal GBM and their
therapeutic value as biomarkers in targeting the CSC subpopulation of GBM could be of
utmost importance to an aggressive cancer that is ultimately untreatable.
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CHAPTER 5.

DISCUSSION

Constitutive Activation of STAT3, NF-κB and Notch Signaling in Glioma CSCs
Promotes Tumorigenesis
Numerous studies support the idea that many types of malignancies, including
glioblastoma, originate from a CSC population that is able to initiate and maintain tumors
[8, 136]. Although CSCs only represent a small fraction of cells within a tumor, their
high tumor-initiating capacity and therapeutic resistance drives tumorigenesis. Therefore,
it is imperative to identify pathways associated with CSCs in order to devise strategies to
selectively target them. In Chapter 2, we described a novel relationship between
glioblastoma CSCs and the Notch pathway, which involves the constitutive activation of
STAT3 and NF-κB signaling. Glioma CSCs were isolated and maintained in vitro using a
previously described adherent culture system [77], and the biological properties were
compared to traditional tumorsphere cultures of CSCs [132, 133]. GBM CSCs exhibited
enhanced CD133, Sox2 and Nestin expression and were ~100 times more tumorigenic in
vivo than monolayer cultured glioma cells. These findings are consistent with previous
studies, in which 100-fold fewer CD133 positive cells of the murine GL261 glioma line
were found to be sufficient to initiate tumors when injected intracranially into mice when
compared to CD133 negative cells [139]. Taken together, these findings demonstrate that
adherent glioma CSCs exhibit characteristics previously described for CSCs grown in
suspension culture and thus provide a valuable model for studying glioma CSC behavior.
The STAT3 and NF-κB pathways have been linked to cancer, and they trigger
critical target genes regulating cell proliferation and survival. Both pathways have been
found to be constitutively active in a number of human cancers including glioma, but
their role in the glioma CSC subpopulation is not well understood [140]. Aberrant nuclear
expression of NF-κB has been found in a panel of GBM cell lines and constitutively high
STAT3 activity has been observed in a number of glioma cell lines and correlated with
poor prognosis [141, 142]. In this study, we identified that these pathways are
dramatically activated in GBM stem cells, and that STAT3 and NF-κB proteins
colocalize in the nuclei of glioma CSCs. Evidence of the functional significance of
STAT3 and NF-κB activation in glioma CSCs was provided by the finding that some of
their known target genes were overexpressed in adherent and tumorsphere CSCs relative
to glioma monolayers. Since targeting these signaling pathways would be a novel
approach in glioma treatment, we examined the effects of two STAT3 inhibitors,
WP1066 and S3I-203, on GBM stem cells. The inhibitors blocked STAT3 tyrosine
phosphorylation and led to the loss of nuclear colocalization of STAT3 and the p65
subunit of NF-NB. In addition, treatment with either STAT3 inhibitor resulted in a greater
growth suppressive effect on glioma CSCs, suggesting that targeted therapy of these key
pathways in glioma CSCs may be possible.
To further investigate potential biomarkers in glioma CSCs, microarray analysis
revealed deregulation of the Notch signaling pathway. Notch is involved in cell fate
decisions throughout brain development and in stem cell proliferation and maintenance,
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and its role in glioma is firmly established [84]. We also defined molecular crosstalk
between the STAT3, NF-κB and Notch signaling pathways in glioma CSCs. While
STAT3 inhibitors reduced expression of Notch-related genes in GBM stem cells, they
increased expression of the negative regulator of Notch, RBPJ. It has been previously
reported that in the developing CNS there is crosstalk between Notch and STAT3
pathways, in which phosphorylation of STAT3 is mediated by the direct binding of
several Hes family members (Notch effectors) to STAT3 [95]. Interestingly, activation of
the Notch pathway led to serine phosphorylation of STAT3 in neural stem cells, but our
studies revealed the constitutive activation of STAT3 in glioma CSCs as determined by
its tyrosine phosphorylation lies upstream of the Notch pathway [134, 135]. In addition,
Notch and NF-κB signaling pathways have been found to collaborate throughout normal
brain development and regulate stem cell renewal and differentiation [94]. We
hypothesize that the interactions of STAT3, NF-κB, and Notch signaling pathways that
occur during normal brain development are deregulated in glioma CSCs. As shown in
Chapter 2, there is crosstalk between these signaling pathways in the glioma CSC
subpopulation that drives gliomagenesis. The constitutive activation of STAT3 and
NF-κB signaling pathways, and the upregulation of the Notch pathway in glioma CSCs
identifies novel therapeutic targets for the treatment of glioma. Future studies will be
required to validate these findings in vivo and decipher the underlying molecular
mechanisms.
Distinct CSC Populations Drive Tumor Heterogeneity and Subsequent GBM
Subclassfication
Although GBM patients present uniform histological phenotypes, the molecular
determinants of disease aggressiveness vary considerably between individual cases.
Genomic profiling of GBM samples in the TCGA database has identified four subtypes,
Classical, Neural, Proneural and Mesenchymal, which are thought to develop as a result
of different CSC populations driving tumorigenesis [120]. Since few biomarkers show
prognostic promise or predict therapeutic response, improved molecular understanding of
the tumor-initiating cells that drive cancer heterogeneity will advance treatment strategies
for the distinct molecular subclasses of GBM. In Chapter 3, we identified two distinct
cancer stem-like cell populations that produce Classical or Mesenchymal GBM tumors
but display identical histological features. Molecular characterization of GBM cells and
their derived tumor tissue revealed a distinct difference in gene expression pattern
between tumors derived from adherent CSC and tumorsphere cultures. Our findings
support recent studies proposing that tumor heterogeneity is a result of CSCs that are able
to self-renew and generate differentiated progeny that compose the bulk of the tumor.
Initially, CD133 was proposed to be the robust marker of brain tumor stem cells, but
recent studies have shown that CD133 does not consistently distinguish tumorigenic and
non-tumorigenic glioma cells, suggesting that distinct CSC subpopulations exist to drive
GBM tumorigenesis [161, 162].
To determine whether adherent CSCs and tumorspheres promote tumor
heterogeneity corresponding to a specific subtype of GBM, we analyzed traditional

74

markers of the Classical, Neural, Proneural and Mesenchymal subtypes. Adherent
CSC-derived tumors were found to promote a Mesenchymal GBM gene signature, while
tumorspheres promoted the Classical GBM subtype like that of the bulk tumor cells. This
is supported by previous findings, in which the genetic profile of tumorspheres was
shown to closely resemble that of the tumor they were isolated from, and the CSCs also
replicated the infiltrating growth patterns observed in primary tumors [174, 175]. To
determine if this molecular heterogeneity is maintained in the conventional
microenvironment of GBM, we performed intracranial injections of GBM6 cells. The
tumor-initiating capacity and molecular heterogeneity of the GBM CSCs by orthotopic
injection were found to closely resemble our previous findings by subcutaneous injection.
The extensive heterogeneity at the cellular and molecular levels of GBM that are found in
tumors produced by CSCs has great significance for the general outcome of the
malignancy; it confounds our understanding of the disease and also contributes to tumor
aggressiveness and poses obstacles to the design of effective therapies [163]. Therefore,
establishing an adherent CSC culture method that exhibits a mesenchymal gene signature
and promotes the initiation and progression of the aggressive Mesenchymal GBM
subtype in vivo, provides a valuable model of the human disease for future studies.
All GBMs are distinguished pathologically from lower grade gliomas by the
presence of necrosis and microvascular hyperplasia, but there is no distinction between
molecular subtypes, which complicates prognosis and therapeutic strategies [164]. To
study the pathology of the Classical and Mesenchymal GBM tumors derived from our
different GBM6 cell cultures, each sample was stained for H&E analysis and the
common GBM prognostic markers GFAP, S100, OLIG2, MAP2 and SYN. The Classical
GBM tumors derived from bulk tumor cells and tumorspheres and the Mesenchymal
tumors derived from adherent GBM stem cells were all diagnosed as High-Grade Glioma
and displayed no differences in H&E staining or marker expression. These findings
reveal the pathological likeness between the molecularly distinct Classical and
Mesechymal xenografts derived from bulk tumor cells and adherent CSCs, respectively.
It also demonstrates the importance of integrative histological and molecular
classification of gliomas in establishing effective treatment regimens for GBM patients.
To identify novel genes specifically deregulated in Mesenchymal GBM tumors
derived from adherent CSC cultures of GBM6 xenografts, we further analyzed our
microarray data. The expression of STAT3 was shown be elevated in the more aggressive
stem cell-derived tumors, which is consistent with our previous identification of STAT3
as a potential therapeutic target due to its constitutive activation in GBM stem cells [154].
STAT3 is a master regulator of genes involved in various steps of tumor progression, so
we sought to identify pathways that STAT3 could potentially regulate within CSCs to
promote gliomagenesis. IPA analysis revealed significant upregulation of several genes
involved in angiogenesis, with ANGPTL4 being of great interest since our lab has
observed elevated expression of ANGPTL4 in xenografts derived from CSCs in other
cancer types [unpublished]. While previous reports suggest EGFR induces ANGPTL4
expression and promotes tumor angiogenesis in malignant gliomas, we found ANGPTL4
activation to be independent of EGFR upregulation in Mesenchymal GBM xenografts
[165]. The important roles of STAT3 and ANGPTL4 in promoting GBM progression and
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vascularization represent potential therapeutic targets in treating GBM and warrant
further molecular characterization.
STAT3 and ANGPTL4 Interact and Function as Biomarkers of the CSC
Subpopulation within GBM Tumors
Mesenchymal GBM is the most aggressive and deadly form of glioma, accounting
for around 30% of GBM cases. The poor survival rate and ineffectiveness of current
therapies may reflect the lack of drug potency on the CSC subpopulation. Therefore, it is
imperative to identify biomarkers associated with CSCs in order to devise strategies to
selectively target them and subsequently block GBM progression. In Chapter 4, we
describe a novel relationship between STAT3 and ANGPTL4 within the stem cell
population of Mesenchymal GBM that drives tumor initiation and progression. We
previously performed microarray analysis and found elevated levels of both STAT3 and
ANGPTL4 in aggressive Mesenchymal tumors formed from CSCs. These results are
consistent with previous findings in Mesenchymal GBM, in which STAT3 was suggested
to be a major regulator of mesenchymal transformation [56]. A robust angiogenesis gene
signature, including ANGPTL4, has also been shown to correlate with the Mesenchymal
subtype of GBM [125]. ANGPTL4 is a secreted, matricellular protein that provides
signals to support many steps of tumor progression, especially angiogenesis [109, 169].
While ANGPTL4 is commonly activated by VEGF or HIF-1, studies have identified
ANGPTL4 as being induced by constitutive activation of STAT3 [114]. This led us to
evaluate the relationship of these proteins within Mesenchymal GBM CSCs. Constitutive
activation and direct interaction of STAT3 and ANGPTL4 was found in cells throughout
GBM xenografts, specifically in CD133+ CSCs when compared to the CD133population. These results are supported by recent studies, which have identified the
requirement of STAT3 for CSC proliferation and survival and the involvement of
ANGPTL4 in maintenance of stem cell niches [80]. Additionally, previous findings in
breast and renal cell carcinoma found that STAT3 activates ANGPTL4 by binding its
promoter and interacting with HIF-1 and other coactivators [115].
STAT3 has been shown to activate ANGPTL4 directly or indirectly through
transcriptional regulation of VEGF and HIF-1 in various human cancers, so we examined
the relationship of STAT3 and ANGPTL4 expression in GBM to patient prognosis and
survival in the TCGA database [27, 28]. High STAT3 and ANGPTL4 levels were
observed in GBM samples when compared to normal brain and low-grade gliomas, and
enhanced expression correlated to short-term survival. Consistent with our findings,
STAT3 is reported to be among the most frequently activated oncogenic proteins in
multiple solid tumor types. More specifically, a large body of data has demonstrated
activation of the typically quiescent STAT3 pathway as being crucial to tumorigenesis
and a predictor of poor prognosis in glioma [55]. ANGPTL4 has been identified as a
prominent gene in in vivo hypoxia gene sets that predict poor outcome in multiple tumor
types. In a study of several epithelial tumor types, ANGPTL4 levels increased as tumors
progressed from local to metastatic disease [107, 108]. In our studies, we found a strong
relationship between poor patient performance and survival and enhanced expression of
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STAT3 and ANGPTL4 in GBM patients. Additionally, our studies revealed a direct
correlation in expression levels of STAT3 and ANGPTL4 within human GBM samples.
These results indicate that the co-expression of STAT3 and ANGPTL4 may have
diagnostic and prognostic utility in GBM. Moreover, since ANGPTL4 is a secreted
protein and detectable by ELISA, in future studies ANGPTL4 levels could be measured
for a non-invasive test of tumor response and diagnosis.
Targeted small molecule inhibitors of STAT3 have previously been shown to
inhibit CSC proliferation and tumorsphere formation as well as sensitize GBM stem cells
to TMZ [81]. We examined the effects of the STAT3 inhibitor WP1066 and the indirect
ANGPTL4 inhibitor Sorafenib, which targets VEGF signaling, on glioma CSCs and
Mesenchymal GBM progression. WP1066 has been shown to have pro-apoptotic and
anti-proliferative activity in glioma and most importantly shown to cross the blood brain
barrier [143, 170]. Sorafenib has proven efficacy for treatment of various cancers and is
currently in clinical trials for GBM [171, 172]. In our study, both drugs blocked the
interaction of STAT3 and ANGPTL4 in GBM stem cells and lead to a decrease in
expression of pro-angiogenic genes as well as stem cell marker genes, which suggest an
important combined role of STAT3 and ANGPTL4 in Mesenchymal GBM stem cell
maintenance. In addition, combined treatment with WP1066 and Sorafenib resulted in an
induction of apoptosis in GBM CSCs. We also found that WP1066 and Sorafenib
individually decreased Mesenchymal GBM cancer progression in vivo, while combined
treatment lead to complete tumor regression. The drugs have not been used in
combination previously, but our individual results are similar to previous studies done
with these inhibitors. WP1066 has been shown to significantly inhibit growth of
malignant glioma xenografts by blocking STAT3 activation and subsequent
pro-proliferative genes [170]. Interestingly, studies show that Sorafenib induced growth
arrest and apoptosis of GBM cells by blocking VEGF and STAT3 signaling [173]. Taken
together, we have identified a significant relationship between STAT3 and ANGPTL4 in
GBM stem cells and their therapeutic value as biomarkers in targeting the CSC
subpopulation of Mesenchymal GBM.
Remaining Questions and Future Studies
While our molecular characterization of GBM cancer stem cells has led to the
identification of distinct tumor initiating populations and novel therapeutic targets in
treating GBM, further study must be done to verify these results. Most of the reports
within this body of work were done using cells or tumor tissue derived from GBM6,
which is a Classical GBM patient xenograft that exhibits overexpression of the VIII
mutant of EGFR. It will be important to study additional patient-derived xenografts that
contain amplified EGFR VIII (such as GBM39) as well as wild type EGFR (such as
GBM10 and GBM12), which are patient-derived GMB xenografts from the laboratory of
C. David James, UCSF. It will be important to establish adherent CSC cultures of these
other xenografts to determine if this is truly a subpopulation of GBM stem cells that
drives Mesenchymal GBM tumor initiation and progression. The upregulation and
interaction of STAT3, NF-κB and ANGPTL4 signaling pathways will also need to be
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verified in additional xenolines to confirm their role in stem cell maintenance and GBM
tumor progression. While the relationship between STAT3 and NF-κB in cancer is well
established, further characterization of the interaction between STAT3 and ANGPTL4 in
GBM should be completed. Constitutive activation of STAT3 has been shown to activate
ANGPTL4 in other cancers by binding its promoter and interacting with HIF-1 and other
coactivators. Therefore, investigating the role of hypoxia and HIF-1 within glioma CSCs
might lead to a better understanding of the novel relationship found between STAT3 and
ANGPTL4 in GBM stem cells.
The aberrant activation of STAT3 and ANGPTL4 has previously been associated
with Mesenchymal GBM, but their specific role in the CSC subpopulations of GBM
warrants further investigation. To determine if STAT3 and ANGPTL4 activation drives
the aggressive mesenchymal gene signature in GBM, gene knockdowns should be created
in adherent CSCs to reveal the essential roles of STAT3 and ANGPTL4 in glioma tumor
initiation and heterogeneity. Our lab has previously attempted to transduce GBM6 stem
cells with a lentivirus-delivered shRNA against STAT3 and ANGPTL4, but knockdown
resulted in widespread cell death. Currently, the lab is creating a doxycycline-dependent
inducible knockdown system specific for these target genes to investigate the effect of
diminished expression of STAT3 and ANGPTL4 on CSCs and tumor initiation.
ANGPTL4 activity following inducible STAT3 knockdown will also be examined to
determine if STAT3 is an essential regulator of ANGPTL4 signaling and subsequent
tumor vascularization. This knockdown system will also be used to determine if
knockdown of STAT3 or ANGPTL4 prevents the Mesenchymal gene signature observed
in adherent GBM stem cells and their derived tumors.
Other genes differentially expressed between adherent CSCs and tumorspheres in
our microarray analysis will be examined in future studies to determine if these genes
also contribute to the mesenchymal gene signature. Our lab has recently identified
Galectin-1, Annexin A1 and Major Vault Protein as being differentially expressed
between the two GBM stem cell populations. These genes are involved in angiogenesis,
stem cell maintenance and drug resistance respectively, and represent genes of interest
that should be investigated further for their roles in CSCs that drive Classical or
Mesenchymal GBM [176-178]. It will also be important to determine if these genes,
along with STAT3, NF-κB and ANGPTL4, could serve as potential drug targets for
treating mesenchymal GBM. The lab will soon be testing the efficacy of combined
STAT3 and ANGPTL4 inhibition on intracranial Mesenchymal GBM tumors using
WP1066 and Sorafenib. If these drugs cross the blood brain barrier and result in tumor
regression, the combined treatment could eventually lead to clinical treatment regimens
for GBM patients. Taken together, further investigation of these genes involved in glioma
CSCs will give insight into the formation of distinct GBM subclasses and future
therapeutic approaches in treating GBM.
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